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ABSTRACT OF DISSERTATION  
 
 
 
THE EFFECT OF CURCUMIN ON CARDIOVASCULAR HEALTH IN OBESE MEN 
 
Cardiovascular disease is the leading cause of death in the United States, and 
conventional treatment often emphasizes pharmaceutical approaches. Research has 
recently started exploring non-pharmaceutical approaches, including nutritional 
interventions. This research study was conducted to test the effectiveness of a novel 
nutritional approach, curcumin, on the improvement of cardiovascular health in young, 
obese males (BMI≥30 kg/m2). This study included 22 men, matched based on BMI and 
randomly assigned to the intervention (n=11) or placebo group (n=11). The intervention 
consisted of 12 weeks of curcumin supplementation (1.0 g/day) with fenugreek added to 
enhance the curcumin bioavailability; the placebo consisted of 12 weeks of equal parts 
fenugreek to that found in the intervention. To determine cardiovascular improvements, 
arterial stiffness via gold-standard carotid-femoral pulse wave velocity (cfPWV), 
endothelial dysfunction via reactive hyperemia index (RHI), and inflammation via 
plasma cytokine concentrations were measured. There were no overall differences in 
cfPWV (p=0.428) or RHI (p=0.951) between groups following the 12 weeks of 
intervention. However, some individuals did respond to the curcumin treatment with 
reductions in cfPWV, while others did not. Subjects who did respond to the curcumin 
treatment (n=6) entered the study with higher baseline values of cfPWV than those that 
did not respond (n=5) (6.81 m/s v. 5.84 m/s, p = 0.045). This suggests a potential role for 
curcumin to improve arterial stiffness in individuals with stiffer arteries at baseline. A 
possible mechanism to explain the difference in responsiveness is a trending increase in 
IL-13 (p=0.052), an anti-inflammatory cytokine that has been associated with 
amelioration of collagen content in the arteries. Also, 12 weeks of curcumin intervention 
resulted in reductions in brachial pulse pressure (p<0.05), a surrogate marker of arterial 
stiffness. This change in brachial pulse pressure in the curcumin group could be 
explained by an increased trend in anti-inflammatory cytokine IL-10 (p=0.071), but 
further studies are required to confirm this finding. Based on the findings of this study, 
curcumin might serve as a non-pharmaceutical intervention to improve vascular health in 
young obese men, especially when arteries are stiffer than age-matched counterparts. 
 
KEYWORDS: Turmeric, Arterial stiffness, Carotid-femoral pulse wave velocity 
(cfPWV), Cardiovascular disease (CVD), Obesity  
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CHAPTER I 
DISSERTATION INTRODUCTION 
Introduction 
 Cardiovascular diseases (CVDs) lead to more deaths in the United States than any 
other cause (226). Large artery stiffness is an independent risk factor for CVD and is an 
overall indicator of vascular health (324). More specifically, carotid-femoral pulse wave 
velocity (cfPWV), a measure of the stiffness of the thoracic and abdominal aorta, may 
serve as a better predictor of CVD than more traditional markers, such as resting blood 
pressure (BP) (216). Additionally, cfPWV is widely accepted as the non-invasive gold 
standard for measuring arterial stiffness in humans (185). Furthermore, vascular 
endothelial dysfunction, which includes an inability of the inner lining of the blood 
vessels to properly dilate and constrict, may contribute to stiffness of the arteries. The 
interplay between arterial stiffness and endothelial dysfunction is not well understood, 
but they are both indicators of vascular health (51, 60). In recent years, as more 
information has been reported on arterial properties and their indication of overall 
cardiovascular health, interest in strategies to reduce large artery stiffness in many 
populations has escalated. However, the contribution of obesity to large artery stiffness 
has not been fully elucidated.  
Thirty-four percent of U.S. adults are classified as obese (114). Obesity has been 
clearly linked to CVD (259) and is associated with increased large artery stiffness (368). 
Some studies have been conducted to assess the ability of exercise and dietary 
interventions to reduce arterial stiffness in this population, but more work needs to be 
done to address CVD associated with obesity. A nutritional intervention of recent interest 
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is curcumin, which has been reported to have beneficial effects in many disease states, 
most notably cancer (18). The benefits of curcumin on cardiovascular health, and 
specifically arterial stiffness, are not well understood. Some studies have reported a 
potential benefit of curcumin in reducing stiffness of the arteries (9, 113, 230, 322), 
though none have evaluated an obese population. Furthermore, reducing arterial stiffness 
could lead to a reduction in risk for developing CVD. A previous study also examined the 
effects of curcumin on endothelial dysfunction, but this was limited to post-menopausal 
(PM) women (8). The present work studied the responsiveness of cardiovascular health to 
12 weeks of supplementation with curcumin in obese men.  
 The purpose of this study was to determine if 12 weeks of curcumin 
supplementation could ameliorate arterial health in young, obese men. The primary 
outcome in this study was non-invasive gold standard arterial stiffness measure, cfPWV. 
We hypothesized that obese males in the intervention (curcumin + fenugreek) group 
would experience significant improvement in arterial stiffening at the 12-week visit when 
compared to obese males in the control group (fenugreek only). 
 Additionally, pulse wave analysis (PWA) and resting blood pressure (BP) 
measures, including aortic BP measures, aortic augmentation index, and brachial BP 
measures, were assessed as secondary outcomes for arterial stiffness. The reactive 
hyperemia index, a measure of endothelial function, was monitored as a secondary 
outcome for vascular health. Furthermore, changes in inflammatory blood profiles were 
assessed because of the association between inflammation and both arterial stiffness and 
endothelial dysfunction (204, 357). We hypothesized that obese males in the intervention 
(curcumin + fenugreek) group would experience: (1) improvements in cardiovascular 
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hemodynamics, (2) improvements in endothelial function, and (3) improvements in 
inflammatory blood markers at the 12-week visit when compared to obese males in the 
control group (fenugreek only).   
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Abbreviations 
ACh: Acetylcholine 
AGEs: Advanced glycation end-products 
AIx: Augmentation index 
AIx75: Augmentation index adjusted for a 
heart rate of 75 
BP: Blood pressure 
BMI: Body mass index 
CCTS: Center for Clinical and 
Translational Sciences 
cfPWV: carotid-femoral pulse wave 
velocity 
CNP: C-type natriuretic peptide 
CVD: Cardiovascular disease 
DBP: Diastolic blood pressure 
DHA: Docosahexaenoic acid 
DHQ: Dietary History Questionnaire 
DXA: Dual-energy X-ray absorptiometry 
EKG: Electrocardiogram 
EPA: Eicosapentaenoic acid 
FMD: Flow-mediated dilation 
FFQ: Food frequency questionnaire 
GSH: Glutathione 
HDL: High density lipoprotein 
HEI: Healthy Eating Index 
HR: Heart rate 
HTN: Hypertension 
IFN: Interferon 
IL: Interleukin 
LDL: Low density lipoprotein 
MAP: Mean arterial pressure 
MRI: Magnetic resonance imaging  
MMPs: Matrix metalloproteinases 
NHANES: National Health and 
Nutritional Examination Surveys 
NIH: National Institutes of Health 
NO: Nitric oxide 
PAT: Peripheral arterial tonometry 
PWA: Pulse wave analysis 
PWV: Pulse wave velocity 
RHI: Reactive hyperemia index 
PM: Postmenopausal 
PP: Pulse pressure 
RFAB: Risk Factor Assessment Branch 
SAS: Statistical Analysis Software 
SBP: Systolic blood pressure 
SD: Standard deviation 
SOD: Superoxide dismutase 
THC: Tetrahydrocurcumin 
TNF: Tumor Necrosis Factor 
 
5 
 
CHAPTER II 
REVIEW OF LITERATURE 
Introduction 
 Cardiovascular diseases (CVDs) persist as the leading cause of death in the 
United States and worldwide (226, 380). Obesity is also a rising epidemic, and with 
obesity, there is a 50-100% higher risk of death than normal weight counterparts, due 
primarily to CVDs (259). Arterial dysfunction, and more specifically aortic stiffness, has 
great predictive power in determining future cardiovascular events and all-cause 
mortality (356). Furthermore, endothelial dysfunction, as measured by the reactive 
hyperemia index (RHI) through peripheral arterial tonometry (PAT), has been associated 
with increased adverse cardiovascular events, including cardiac death, myocardial 
infarction, revascularization, or cardiac hospitalization (277). Therefore, identifying 
interventions for preventing or reducing arterial stiffness and endothelial dysfunction in 
humans may have immense clinical significance in the reduction of overall CVD (58).  
Some studies have looked at using nutritional interventions to reduce arterial 
stiffness. Evidence from a few studies has suggested that a novel nutritional intervention, 
curcumin, serves to protect against various cardiovascular problems, though the 
mechanisms are not well understood (378). The impact curcumin plays on reducing the 
stiffness of the arteries may be partially responsible for this protective effect. Curcumin 
has been found to affect vascular health in mice specifically by: (1) reducing the stiffness 
of the arteries, as measured by PWV; (2) ameliorating endothelial dysfunction associated 
with diminished nitric oxide (NO) bioavailability; and (3) decreasing oxidative stress 
(113). Studies in PM women have shown that curcumin supplementation has resulted in 
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significant improvements in arterial compliance and endothelial dysfunction similar to 
aerobic exercise, a well-established method for reducing arterial stiffness (8, 9, 322).  
To date, studies reporting the positive effects of curcumin on arterial stiffness and 
endothelial function have been limited to aged male mice and aged women but have not 
considered the effects of curcumin on obese individuals or men. Furthermore, a majority 
of studies looking at interventions for arterial stiffness have focused on aged populations. 
More recently, the link between obesity and arterial stiffness was reported, but few 
studies have focused on mechanisms that underlie arterial stiffness and nutritional 
interventions to treat arterial stiffness in obese populations. The present review is 
designed to look at how nutritional interventions affect large artery stiffness and 
endothelial function of overweight and obese individuals, with specific interest given to 
curcumin. 
Defining Arterial Stiffness 
Arterial stiffness, or arteriosclerosis, is an encompassing term that includes the 
compliance, distensibility, and elasticity of the arteries (317). Distensibility of the arteries 
is determined by the relative change in diameter of a vessel given a certain amount of 
pressure, whereas compliance is the absolute change in diameter given a certain amount 
of pressure. Moreover, “elastic modulus” refers to the pressure change required to 
increase the diameter of the vessel 100% (247). Though these terms may be used 
synonymously at times, arterial stiffness is the more encompassing, broader term that 
addresses these various aspects related to the rigidity of the arterial walls. Arterial health 
cannot be downplayed, as it has an integral role in the determination of overall 
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cardiovascular health. Throughout the cardiac cycle, the ability of the arteries to expand 
and recoil will be determined by the stiffening of the arteries. 
Arterial stiffening is a known phenomenon that happens due to various causes, 
but it does not impact the arteries of the body systematically. The arterial system can be 
broken down categorically: large elastic arteries, medium-sized muscular (or peripheral) 
arteries, and small arterioles. The large elastic arteries, such as the thoracic aorta and 
carotid arteries, are characterized by their striking ability to respond to changes in 
pressure due to their high elastin content, which allows for greater adaptability than other 
arteries in the body. The muscular arteries, such as radial and splenic arteries, are 
characterized by decreased elastin content and increased vascular smooth muscle. The 
arterioles, the smallest arteries, connect to capillaries and are responsible for more 
resistance than the other two functional groups of arteries. Studies have shown that the 
large elastic arteries may be the primary target of arterial stiffness with age and that the 
muscular arteries may not be as readily affected as the large elastic arteries (39). This is 
not to suggest that no change occurs at the peripheral arteries with age, but in cases 
excluding peripheral arterial disease, the arteries of the periphery are not as easily or 
dramatically stiffened. Additionally, peripheral arteries are not as affected by traditional 
methods for lowering arterial stiffness as the large elastic arteries (135, 328). This could 
possibly be explained by the differing structure of the arteries along the arterial system, 
including collagen, elastin, and vascular smooth muscle content. Furthermore, the roles 
of the arteries along the arterial tree may also determine their sensitivity to stiffness. The 
large elastic arteries buffer pulsations, peripheral arteries modify the propagation 
velocity, and arterioles are reflection sites for the pulse wave (281). During youth, when 
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arteries are more compliant, large central arteries, such as the aorta, are more elastic in 
nature to buffer pulsations, whereas peripheral arteries are more rigid for their 
functionality in affecting the velocity of blood flow (39). The dilating capacity of the 
large elastic arteries is required to be 3-4.5 times as great as that of the muscular arteries, 
which suggests that the elastic arteries fatigue more with aging because of increased 
workload placed upon them throughout life (246). Consequently, the changes in arterial 
stiffness that primarily affect the large elastic arteries are likely a result of both the 
structure and function of these arteries. With the structural and functional changes that 
occur in these large elastic arteries, a consequent change in the pulse pressure wave will 
occur.  
When the left ventricle of the heart contracts, blood is ejected from the heart into 
the ascending aorta. This causes the aorta to expand, and a pulse pressure wave is sent to 
the peripheral arteries and arterioles by way of the large elastic arteries. The stiffer an 
artery is, the faster the pulse pressure wave will travel. In contrast, healthy arteries are 
elastic and compliant in nature, allowing for necessary adjustments in blood flow to occur 
quickly and readily. Thus, healthy arteries show slower traveling pulse wave velocities 
than arteries that are stiffer. As the pulse wave reaches the periphery, where greater 
impedance occurs, a reflected wave is sent back to the aorta (74). Together, the initial (or 
incident) pulse wave and the reflected wave make up the pressure waveform. When 
arteries are stiffer, this waveform will be augmented by the increased transmission 
velocities; the reflected wave will arrive earlier in the aorta, causing pressure to augment 
during systole (217). This will, in turn, cause aortic systolic pressure to increase and 
aortic diastolic pressure to decrease (246).  
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Arterial stiffness, as measured by cfPWV, is an important risk factor, independent 
of conventional risk factors, in determining cardiovascular events (201). Additionally, it 
is predictive in determining cardiovascular and all-cause mortality (186). Remarkably, a 
rise in  aortic PWV by 1.0 m/s increases cardiovascular risk by 15% (356). Therefore, 
vascular stiffness is very important in determining cardiovascular risk. It should also be 
noted that vascular dysfunction does not merely affect the heart but can also cause 
impaired blood flow to the brain, kidney, and other organs, which could lead to cognitive 
decline, renal impairment, or other problems throughout the body (213, 254, 326). 
Arterial health is often overlooked in the role that it plays in the global health of an 
individual, so more attention needs to be given to screening for arterial stiffness.  
Known Contributing Factors to Arterial Stiffness 
 Arterial stiffness leads to known structural changes of the arteries, but the 
mechanisms contributing to the stiffness are still under investigation. Arteries are 
composed of three layers: the tunica adventitia, the tunica media, and the tunica intima. 
Additionally, endothelial cells separate the arterial wall from the blood. As discussed 
earlier, the arteries have a different structure based on their function. The degree to which 
each of the known contributing factors to arterial stiffness can impact the artery is 
dependent upon the location and function of the artery. In general terms, stiffened arteries 
have been marked by: increased collagen content, decreased elastin content, 
inflammatory activity, increased matrix metalloproteinases, increased content of reactive 
oxygen species, and increased advanced glycation end-products (AGEs). 
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Collagen and Elastin 
Proteins known as collagen and elastin, found within the extracellular matrix of 
the arteries, are two of the most well-known elements of the arterial wall that are affected 
with stiffness. Elastin serves to allow for pliability of the arterial wall when pressures are 
loaded during the cardiac cycle, whereas collagen provides structural support and 
strength when high pressures are placed on the arteries (128). Both collagen and elastin 
are stabilized by their ability to cross-link (273). This cross-linking allows for durability 
of these proteins present in the artery, but when the cross-linking is affected, structural 
damage at the artery can enhance the stiffness of the arteries. Arterial stiffness is 
amplified as the elastin fibers are fragmented or thinned (128). Elastin is found in higher 
content in the portions of the arterial tree that are closer to the aorta (153), allowing for 
resilience and extensibility, as well as recovery from stretch (90). In contrast, collagen 
functions to limit the distension that is able to occur when increased loads are placed on 
the arteries and the pressure exceeds physiologic loads (377). Therefore, both proteins are 
important for the integrity of the arterial wall – elastin working more at lower pressures 
and collagen working more at higher pressures. One study suggested that alterations in 
elastin are more likely to lead to changes in the geometry of a vessel but not changes in 
the mechanical properties, whereas alterations in collagen are more likely to have an 
effect on the mechanical properties while having little effect on the geometry, which will 
cause collagen alterations to have a greater effect on the stiffness (91). When the balance 
of these proteins is offset in cases of arterial stiffness, the arteries become more rigid 
from higher collagen content and lower elastin content. 
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Inflammation 
 Large artery stiffness has been directly associated with acute and chronic 
inflammation (204, 357). Inflammation is associated with the structural changes that 
occur in the artery, as inflammation leads to increases in collagen production and 
decreases in elastin production, corrupting the normal balance that exists between 
collagen and elastin in the arteries (159). Inflammation reportedly affects the structural 
components of the arteries through matrix metalloproteinases (MMPs), which are 
secreted by cells such as fibroblasts, osteoblasts, endothelial cells, macrophages, 
neutrophils, and lymphocytes (352). The arterial wall is specifically affected by MMPs 
that are secreted by vascular smooth muscle cells and macrophage foam cells (386). 
MMPs are catabolic in nature, and they function as collagenases, elastases, and other 
factors that indirectly degrade the collagen and elastin content in the arteries (89). 
Therefore, inflammation leads to structural deterioration of the arteries, which can further 
promote stiffening. Activation of the NFκB pathway induces transcription of pro-
inflammatory cytokines, such as IL-1β, IL-6, IFN-γ, and TNF-α, which directly affects 
the inflammation of the arteries (188). Inflammatory factors are often present in states of 
arterial stiffness, though it is not yet known whether a reduction in chronic inflammation 
at a vascular level will improve large elastic artery stiffness (109). However, the acute 
effects of a known anti-inflammatory drug, aspirin, reported that reductions in 
inflammation nullified acute increases in aortic arterial stiffness (357). In this 
randomized, placebo-controlled study, a Salmonella typhi or sham vaccination was 
administered; the Salmonella typhi vaccination increased cfPWV by 0.43 m/s in 
association with pro-inflammatory markers, C-reactive protein (CRP), Interleukin (IL)-6, 
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and MMP-9. In contrast, when participants were pre-treated with 1200 mg aspirin 
treatment, neither cfPWV nor the pro-inflammatory markers were increased. The authors 
report a cause-and-effect relationship between acute systemic inflammation and aortic 
stiffness. They speculate that inflammation could affect aortic stiffness through an 
unfavorable effect of inflammation on NO bioavailability, MMPs acting upon either the 
structural or functional changes of the aortic wall, or through further inflammatory 
cytokines that are not measured within the study. The role of chronic inflammation on 
aortic stiffening is still under investigation. 
Advanced Glycation End-Products 
Advanced glycation end-products (AGEs) also have an effect on collagen and 
elastin in the artery. These AGEs form irreversible cross-links with both collagen and 
elastin, leading to more rigid arteries (163). Cross-linking with AGEs results in a reduced 
capacity of collagen and elastin to turnover, leading to an accumulation of collagen and 
elastin molecules that are unable to function properly within the artery (353). When 
elderly individuals (163) and rodents (316) were treated with an agent that breaks the 
cross-linking due to AGEs, it was found that arterial stiffening was attenuated. Moreover, 
in hypertensive subjects, AGEs are associated with aortic stiffness independent of age 
and BP (207). In type 2 diabetics, AGEs are increasingly prevalent in the extracellular 
matrix of the arteries, and the formation of AGEs on lipids can become a relevant 
concern (125). Specifically, AGEs form on LDL and can reduce NO production, which 
suppresses LDL uptake and clearance and promotes dyslipidemia in diabetics (54, 125, 
264). Furthermore, type 2 diabetics have increased aortic stiffness, where obesity is a risk 
factor, and weight loss of ~8% has been reported to improve arterial stiffness in this 
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population. Therefore, the association between AGEs and arterial stiffening is clear; 
however, the mechanisms of AGEs activation impacting arterial stiffening has not been 
completely elucidated (109).  
Oxidative Stress 
Oxidative stress has also been identified as a key mechanism of arterial stiffness, 
though its exact involvement has not yet been elucidated (180, 243, 289). Oxidative stress 
is characterized by an imbalance between reactive oxygen species and the antioxidant 
defense capacity, and it leads to cellular damage and dysfunction (111). Specifically, in 
mice, superoxide production is increased in the aorta (302), which is believed to 
contribute to arterial aging (111). Increased superoxide production within the aorta is 
associated with increased secretion of inflammatory cytokines, suggesting that oxidative 
stress may contribute to vascular aging by promoting inflammation (110). Even when 
other contributing factors to arterial stiffness are taken into account, oxidative stress is 
positively associated with arterial stiffness (256). A study looking at the responsiveness 
of the arteries to statin treatment found that reductions in arterial stiffness were correlated 
with reductions in oxidative stress (r = -0.340, p = 0.003) (360). Another study looking at 
arterial stiffness in aging mice indicated that that older mice with increased aortic PWV 
had higher levels of oxidative stress, collagen expression, pro-inflammatory cytokines, 
and AGEs (111). When aged mice with increased arterial stiffness were treated with 
TEMPOL, an antioxidant which replicates the action of superoxide dismutase (SOD), 
arterial stiffness was ameliorated, endothelial function was restored, collagen levels were 
reduced, inflammation was reduced, and oxidative stress was decreased. The ability of an 
antioxidant to normalize vascular function in old mice suggests that oxidative stress may 
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be playing a crucial role in the development of arterial stiffness. While the relationship 
between oxidative stress and arterial stiffness has not been clearly deduced, oxidative 
stress seems to have an effect on the arterial stiffness progression. 
Nitric Oxide 
 The role of NO in arterial stiffness is still being explored. Functional changes that 
occur with vasoactive properties of the arteries may be a result of NO bioavailability, and 
they may occur apart from structural changes within the artery (373). A study looking at 
blood flow variations in humans suggested that arterial stiffness is regulated by the 
release of NO (37). Local vasoactive mediators released from the endothelium influence 
smooth muscle tone of arteries and can functionally affect arterial stiffness (370). In rats, 
inhibiting NO synthase with L-NG-Nitroarginine Methyl Ester (L-NAME) significantly 
increased PWV acutely, and additional increases were seen after three weeks on L-
NAME treatment while controlling for associated changes in BP (108). In this rat study, 
it was suggested that the endogenous NO system must be functioning properly to 
preserve vascular compliance.  Additionally, NO has been shown to contribute to arterial 
elasticity (172). When basal NO production by the endothelium was inhibited in humans, 
arterial stiffness, as measured by augmentation index (AIx) (371) and PWV (172), were 
increased. Moreover, exogenous administration of foods rich in nitrates and nitrites can 
affect the nitrate-nitrite-NO pathway, and produce bioactive NO (302).  Administering 
nitrite supplementation in middle-aged and older adults has resulted in improved arterial 
compliance and endothelial function (80). Therefore, the ability to modulate NO has been 
associated with the ability to affect arterial health. 
 
15 
 
Risk Factors for Increased Arterial Stiffness  
Non-modifiable Risk Factors 
Age 
Age is known as the leading risk factor for arterial stiffness and CVD risk (229). 
Most of the research to date that has been conducted on arterial stiffness has focused on 
aged populations, as aging with increased stiffness in the arteries is common to all 
people, and the elderly are one of the most readily available populations for studying this 
common phenomenon. A study showed that, throughout the lifetime, cfPWV increases by 
roughly 0.1 m/sec each year, which is equivalent to about 1% per year (26). However, 
after age 55, some studies have shown that a more rapid increase starts to occur (179, 
228). One study showed that the percentage of individuals with abnormal cfPWV rises 
from a few percent in individuals under the age of 50 to 70% after the age of 70 (215).   
Race 
Racial differences exist in vascular health. Black Americans have been shown to 
exhibit higher arterial stiffness, as measured by PWV, as well as greater endothelial 
dysfunction, as measured by the RHI via EndoPAT, even after adjustments are made for 
BP (224). Interestingly, one study looked at whether the differences that exist between 
African-American men and White men could be attenuated with exercise (138). They 
found that cfPWV was not significantly different at baseline in either group but that 
peripheral PWV responded to exercise in White men, yet it did not in African American 
men. Independent of BP, they conclude that racial differences exist in the arterial 
response in the peripheral vascular system, presumably due to blunted vasodilation in 
African American males. Also, a study conducted in Brazil looked at arterial stiffness in 
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four different ethnic groups: American Indians, individuals of Caucasian descent, 
individuals of African descent, or Mulatto (racially mixed) individuals (75). They found 
that individuals of African descent had higher PWV and BP than the other three groups. 
Additionally, when data were analyzed with the removal of hypertensive individuals, 
they found that American Indians had lower adjusted PWV values than the other groups, 
and individuals of African descent still had higher PWV values independent of BP. 
Accordingly, there is solid evidence to suggest that individuals of African descent are 
more apt to arterial stiffness than other individuals. More research needs to be done to 
elucidate whether other ethnicities are at risk for greater arterial stiffness.  
Sex 
Several studies have suggested that women have significantly stiffer and less 
compliant arteries than men (71, 240, 278). While some studies would suggest that this is 
true during all points of life, other studies only observed increased arterial stiffness in 
older, or PM, women when compared to men (123, 359). On the other hand, a study 
looking at sex differences in men and women pre- and post-puberty found that 
prepubescent females had stiffer arteries than their prepubescent male counterparts but 
that there was no difference in males and females after puberty (6). They concluded that, 
as females age, their large arteries become more distensible, whereas, as males age, their 
arteries become stiffer. They suggest that these differences are due to sex-specific 
steroids. They recognize that elderly women have stiffer arteries and suggest this is due 
to intrinsic differences between the sexes. Current evidence suggests that women may 
have stiffer arteries than their age-matched male counterparts, but this may not be true of 
all decades of life.  
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Modifiable Risk Factors 
Obesity 
Obesity is an independent risk factor for CVD (146) and arterial stiffness (384). 
Obesity is often defined by body mass index (BMI). BMI is simply determined by 
dividing weight in kilograms by height in meters squared (kg/m2). While BMI can be 
limiting in that it does not measure the body composition of an individual, it is the 
measure most commonly used to define overweight and obesity (275). By these 
standards, a normal weight individual would have a BMI of 18.5-24.9 kg/m2, an 
overweight individual would have a BMI of 25.0-29.9 kg/m2, and an obese individual 
would have a BMI greater than or equal to 30.0 kg/m2 (59). Studies have shown that 
obesity, as defined by BMI, is linked to an increase in arterial stiffness independent of 
blood pressure, ethnicity, and age (280). Previous work has suggested that the age of 
obesity development may play a role in the degree of vascular damage found, although 
the mechanisms are not yet understood (1, 73). Nonetheless, individuals as young as 20-
30 years have increased cfPWV compared to their normal weight counterparts, as 
determined by BMI (347). Furthermore, when healthy 20-40 year old individuals 
experienced two year weight gains, associated increases in cfPWV progression 
independent of age and BP were also seen (367). Furthermore, abdominal adiposity, as 
determined by waist circumference, shows a stronger relationship with increases in 
arterial stiffness than overall obesity (as determined by BMI), presumably due to 
inflammation or insulin resistance, leading to increased AGEs (280). The association 
between abdominal adiposity and arterial stiffness may be a possible mechanism by 
which central adiposity leads to increased risk for CVD (287). While some studies have 
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pointed to the importance of the age of obesity onset, other studies have suggested that 
long lasting abdominal adiposity is not required to observe stiffening of the arteries (287). 
Increased body weight, BMI, waist and hip circumference, and waist-to-hip ratio are 
strongly correlated with higher PWV (368). Due to the limiting nature of using BMI as an 
indicator of body composition, direct measures of body fat may be a better alternative in 
truly classifying obesity. Large artery stiffness correlates with body fat percentage as 
measured by skinfold calipers (2). In children, body fat percentage, as assessed by Dual-
energy X-ray absorptiometry (DXA), was independently and positively associated with 
PWV (282). In older adults, DXA measures of total fat mass were independently and 
positively associated with PWV (325). Together, these studies show a strong link 
between various parameters of obesity and arterial stiffness. 
Hypertension 
Hypertension (HTN) has been associated with decreased compliance of the 
arteries (192). While HTN and arterial stiffness are both common to aging, HTN has been 
shown to accelerate the arterial stiffening process, especially when it is uncontrolled. A 
study of both hypertensive and normotensive subjects showed that hypertensive subjects 
had a greater progression in PWV with aging than their normotensive counterparts over a 
six-year follow up period with treatment for HTN (38). However, when BP was 
successfully controlled with medication, PWV progression was more than three times 
slower in the individuals with well-controlled BP than individuals who were on 
medication yet did not show well-controlled BP. Therefore, a clear association between 
arterial stiffness and BP seems to exist. Traditionally, it was believed that HTN led to 
aortic remodeling and stiffening as well as vascular smooth muscle cell hypertrophy 
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(251). However, reduced arterial elasticity has been shown to progress to HTN after 
looking at a six year follow-up of normotensive men and women (189). Recently, in a 
study observing mice with diet-induced obesity, the mice presented with arterial stiffness 
before they presented with HTN (363). Therefore, there has been much question as to 
which comes first, HTN or arterial stiffness. It is imperative to develop a better 
understanding of what is happening mechanistically in these two conditions to understand 
this relationship better (119).   
Physical Activity 
Physical activity has been shown to improve cardiovascular heath as a whole. In 
one study of aging individuals, it was discovered that older individuals who engaged in 
regular endurance exercise habitually presented with greater arterial compliance than 
their age-matched counterparts; they concluded that habitual vigorous aerobic exercise 
can be protective against the regular progression of arterial stiffening that occurs with age 
(329). In this study, it is important to note that decreased arterial compliance with aging 
was common to all individuals, whether they were regular exercisers or not, but the 
arterial compliance was significantly improved in men that participated in habitual and 
vigorous endurance exercise (vigorous aerobic-endurance ≥ 5 times per week) yet not in 
men who were recreationally active (light to moderate exercise ≥ 3 times per week). 
Also, a cross-sectional study looking at habitual physical activity in hypertensive subjects 
indicated that physical inactivity was positively correlated with arterial stiffness, as 
measured by both PWV and AIx (245). Physical activity was found to be a significant 
predictor of both AIx and PWV. Many studies have further explored the possible benefits 
of various modes of exercise interventions in reducing arterial stiffness in obese 
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populations, and several have reported significant reductions in arterial stiffness 
following exercise interventions, but these studies are beyond the scope of this review 
(33, 142, 164, 202, 206, 220, 354). Taken together, the above studies suggest that 
physical activity plays an important role in overall arterial health.  
Smoking 
Smoking can dramatically impact arterial health (170, 198). AIx is significantly 
higher in chronic smokers than nonsmokers; in effect, simply smoking one cigarette is 
potent enough to raise arterial stiffness on an acute basis (198). Furthermore, a study 
found that second-hand smoke is powerful enough to change elastic properties of the 
aorta of the passive smokers, though PWV was not measured (314). Additionally, another 
study indicated improvements in arterial stiffness, as measured by AIx (but not PWV), 
after four weeks of successful tobacco cessation (272). Interestingly, in smokers that quit 
but were unsuccessful, AIx was increased from initial smoking levels after resuming 
smoking. Moreover, when looking at cross-sectional measures of smokers, ex-smokers, 
and non-smokers, current and ex-smokers had higher PWV and AIx measures than 
nonsmokers; however, duration of smoking cessation had a significant negative 
correlation with PWV, and individuals who had been ex-smokers for more than 10 years 
showed PWV measures that were not higher than nonsmokers (154). Therefore, while 
smoking has been shown to have negative effects on arterial stiffness, cessation can help 
ameliorate these effects. 
Dietary Habits 
Several dietary habits have been associated with increased arterial stiffness. 
Populations with lower salt intakes have shown smaller increases in PWV with age than 
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those that have high salt intakes (29). In a study examining hypertensive subjects cross-
sectionally, individuals who were identified as being salt sensitive had decreased arterial 
compliance compared to those who were salt resistant (93). Also, higher garlic 
consumption has been shown to lead to smaller increases in PWV with age (53). On the 
other hand, chronic and acute coffee consumption have been shown to contribute to 
arterial stiffness, though the PWV changes are transient after acute consumption (253, 
358). Higher fish consumption in Japanese fishing and farming villages was associated 
with lower cfPWV (132). Alcohol consumption has shown some differing effects on 
arterial stiffness. One study showed that alcohol consumption had a J-shaped association 
with cfPWV in men (300). Thus, they concluded that moderate alcohol consumption (4-
21 glasses/week) could lead to a decreased risk for cardiovascular disease, while more-
than-moderate consumption (22-58 glasses/week) was associated with an increased risk. 
Another study found that acute consumption of red wine decreased arterial stiffness when 
compared to acute consumption of non-alcoholic red wine (PWV decreased by 0.7 m/s, p 
< 0.05; AIx decreased by 4%, p < 0.05), which was still significant after adjusting for BP 
(197). However, this study also concluded that, in chronic drinkers, excessive weekly 
intake ( > 210 g in men and > 140 g in women) for at least one year increased central BP 
and AIx in men only. Therefore, these studies seem to agree that excess alcohol intake is 
associated with arterial stiffness, though moderate intake may be associated with reduced 
stiffness. Lifestyle decisions regarding nutrition can considerably impact arterial health. 
Furthermore, nutritional intervention studies have shown improvements in arterial 
stiffness (255). Therefore, making nutritional changes at any point in life should be 
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advocated for to improve arterial health. Specific nutritional interventions will be 
discussed below.  
Other Risk Factors 
Some other conditions have been associated with arterial stiffness, including 
various disease states and compromised functionality of different systems of the body. 
Certain disease conditions, such as type 1 and type 2 diabetes, dyslipidemia, heart failure, 
end-stage renal disease, and atherosclerosis have been associated with increased arterial 
stiffness (40). Also, elevated fasting glucose, higher HR, and lipid disorders are 
specifically associated with a stiffer aorta (215). Considerations for these various disease 
states and conditions is beyond the scope of this review. 
Assessing Arterial Stiffness 
Pulse Wave Velocity 
Pulse wave velocity (PWV), a direct measure of arterial stiffness, is considered 
the gold standard for measuring arterial stiffness, and it is both valid and reliable (186). 
PWV serves as a predictive measure for both cardiovascular events and overall mortality 
(356). Knowing the speed of the pulse wave through different parts of the body gives 
indication of the health of the arteries. PWV is a simple calculation that looks at the 
transit time of the pulse wave through the body over the length the pulse wave is 
traveling. There are various ways to measure PWV, but the measure of interest for this 
review will be that which is taken by way of applanation tonometry. 
 To measure PWV, Doppler probes (or tonometers), are generally placed on two 
different arterial locations of the body. For example, the gold standard for measuring 
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central PWV utilizes the carotid and femoral arteries and gives an indication of the 
stiffness of the aorta. Doppler probes allow for applanation tonometry, whereby 
applanation means, “to flatten”, and tonometry means, “measuring of pressure” (232). By 
placing pressure on the artery with the tonometer, the artery is flattened against the 
underlying bone (194). The arterial pressure is transmitted from the vessel to the 
tonometer, which contains a strain gauge that allows for a pressure waveform to be 
recorded, and digital images are recorded for analysis (232). Pulse wave transit time is 
accounted for by the difference in arrival time of the pulse wave from the proximal to the 
distal site and is determined by looking at the foot of each wave (foot-to-foot method). If 
the carotid-femoral pulse wave velocity (cfPWV) is used, probes placed on each of these 
sites will reflect differing waves at each site. Computer systems, such as that which 
accompanies Sphygmocor, have been developed to calculate the change in time from the 
foot of one wave to the foot of another. The distance between the two arterial sites is 
measured with a measuring tape by the investigator, using standardized anatomical 
markers on the body, and is recorded in the program. Sphygmocor uses this simple 
calculation to determine PWV: distance between two sites / Δ time between two waves. 
For an average middle-aged adult, a PWV of 4.0 m/s in the ascending aorta, 5.0 m/s in 
the abdominal aorta, and 8.0 m/s in the iliac arteries is to be expected. cfPWV is used as a 
global estimate of PWV through the entire aorta (56). Normal cfPWV measures have 
been reported as 6.0 m/s in individuals younger than 30 years of age and up to 10.0 m/s in 
individuals older than 70 years of age (271). This is a crucial measure for understanding 
the central arterial stiffness, as it takes into account the large elastic arteries, and most 
notably, the aorta. Other sites have been recognized as good sites for determining 
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peripheral arterial stiffness. While this method does serve as the gold standard for 
measuring arterial stiffness, it does have some limitations. The most notable limitation is 
that the length of the arteries, which are measured on skin surfaces and based on 
reference markers, may not be the most accurate measurements for the length of deep 
arteries. When abdominal obesity or large bust size is present, this can be even more of 
an issue (346). If the vessel length estimation is off, this could alter the PWV measure 
(274). Also, acute raises in BP or heart rate (HR) can affect the PWV readings (27, 184). 
However, taking the two readings in immediate succession can reduce changes in HR, 
but if changes in HR > 5 beats per minute occur, additional readings should be taken 
(186). While changes in BP have also been shown to affect PWV in normotensive 
subjects more than hypertensive subjects (244), no parameters are set for acceptable 
changes in BP between readings because a second BP reading is not taken at each site. It 
is generally recommended that repeated measures of PWV are taken at the same time 
each day to limit changes in PWV due to BP fluctuations associated with eating; 
measurements should be taken 3-4 hours after a meal (unless they are taken first thing in 
the morning), and subjects should not consume caffeine within three hours of testing to 
limit changes in BP and HR (346). Therefore, some of the limitations present with 
cfPWV can largely be controlled with careful consideration taken by the tester. Despite 
the limitations that exist, cfPWV is still considered the best option for determining 
arterial stiffness.  
Pulse Wave Analysis 
Pulse wave analysis (PWA) is often measured with the same equipment as, and 
measured in conjunction with, PWV. PWA is commonly taken at the radial pulse with an 
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applanation tonometer; while carotid measures are obtainable, they require a much higher 
level of expertise to extrapolate (64). After a waveform is measured at a peripheral site, a 
validated generalized transfer function is applied to this waveform to indirectly produce a 
central pressure waveform (296). From this conversion, a measure of central BP, central 
PP, and AIx is generated, along with various other indices that have been used to classify 
arterial stiffness and compliance. AIx is one of the most widely used measures that is 
collected during the PWA. AIx is a central hemodynamic index that is predictive of 
cardiovascular events and mortality (355). A measure of AIx is determined by the 
difference between the second and first systolic peaks expressed as a percentage of PP 
(186). This measure is often expressed with regard to HR of the individual (AIx75), as 
AIx is highly influenced by HR. One limitation with AIx is that it may not be a suitable 
measure of cardiovascular risk in individuals over the age of 60 (214). AIx values 
decrease after age 60, whereas cardiovascular risk and cfPWV increase dramatically, 
suggesting that AIx may not be a sensitive marker for arterial stiffness after age 60 (205, 
217). Another major limitation that exists with this technique is that the generalized 
transfer function has a range of error (232). This is due in part to assumptions that are 
made in calculating the generalized transfer function (186). Also, an assumption is made 
in determining the reflection site of the incident wave, as this site is theoretical, and this 
assumption has proven problematic in some instances (210). On the other hand, if AIx of 
the carotid artery is attainable, no transfer function is required; however, much training is 
required and these carotid measures are considerably more difficult to obtain (64).  
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Pulse Pressure 
Pulse pressure (PP) is determined by subtracting diastolic blood pressure (DBP) 
from systolic blood pressure (SBP). As arteries become stiffer, PP has been used as a 
marker to indicate the rigidity of the walls of the arteries. PP is one of the easiest, most 
attainable, and cheapest ways to study arterial stiffness. To understand why PP increases 
with stiffening of the arteries, the speed at which cardiac pulse waves travel down an 
artery becomes very important. These arterial pressure waves are composed of two 
different waves: the incident wave initiated by the heart, which will travel away from the 
heart, and the reflected wave, which is the wave that is returned from the periphery (247). 
When considering a very distensible and compliant artery, cardiac pressure waves that 
travel down the artery travel slowly, and reflection of the pressure waves happens late, 
during diastole. On the other hand, a stiff artery causes cardiac pressure waves to travel 
quickly, triggering the reflected wave to merge with the original wave in systole, thus 
causing systolic pressure to increase and diastolic pressure to decrease. Therefore, PP will 
increase as the arteries become stiffer (235). PP is known to increase with age and serves 
as a good predictor of cardiovascular events in people over the age of 50 (118). Brachial 
PP is very practical, but it is most appropriately used as a surrogate marker in clinical 
settings if more sophisticated technology is unavailable (52). Central PP, as determined 
by the above PWA methods, is believed to be a better indicator of arterial stiffness and 
cardiovascular risk, as it measures PP at the aorta rather than the brachial artery (194). 
Thus, brachial PP serves as a surrogate marker of arterial stiffness, but central PP may be 
a better predictor of cardiovascular events when appropriate devices are available for 
measurement. 
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Ultrasound  
 Ultrasound can also be used to measure arterial compliance, a particular facet of 
arterial stiffness, though it is not used as frequently as the methods described above. 
Ultrasound measurements take into account both the distensibility and compliance of the 
arteries. However, only local measurements can be taken, and not all arteries are 
appropriate for such measurements. Due to the ability to only reach surface arteries with 
ultrasound equipment, only superficial arteries can be measured through ultrasound; 
namely, the brachial, femoral, and carotid arteries are commonly used. Diameter changes 
in the artery are determined by capturing images from ultrasound, and then these images 
are used in conjunction with a BP measurement to determine compliance (44). 
Compliance is defined as the change in volume over the change in pressure. Ultrasound 
equipment is able to provide more accurate measures of the length of the arteries than are 
provided with the external measures from a measuring tape, as described above with 
PWV. Limitations with this kind of equipment include: the expense of the ultrasound 
equipment, the resolution of the photos taken by the equipment, and the ability to 
determine volume changes based on the images taken (350). Additional concerns include: 
the ability of the operator to get meaningful images, reproducibility of the measurements, 
and lack of portability (194). Therefore, the limitations and concerns associated with this 
equipment may not make it the best option for determining arterial stiffness in clinics or 
laboratory settings.  
Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is another method for measuring local arterial 
stiffness, though it is also not used as widely as other methods. Like ultrasound, images 
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are captured of a certain artery, and then the images are used to determine distensibility 
and compliance of that artery. Measurements of diameter are, in turn, used to determine 
changes in volume over changes in pressure. Unlike ultrasound, MRI can be used to 
assess deep arteries, rather than simple surface measurements; thus, MRI studies have 
focused much attention on the aorta. MRI is advantageous in that, when compared to 
arterial length measurements that use a measuring tape, more accurate measurements of 
the artery can be determined. Instead of attaining measurements on outer surfaces of the 
body, MRI imaging allows for far more accurate measurements following the length of 
the artery (56). Nevertheless, MRI equipment is expensive and is often impractical for 
use in laboratory and clinical settings (194). Furthermore, other limitations make this 
technique somewhat less respected in practice, such as a need for: standardized software, 
standardization of techniques, well-determined sampling points, resolution of images, and 
a means to measure along vessels that are not straight (364). Though the potential for 
MRI equipment is clearly evident, the practical use of such equipment and need for 
validation limit its ability to be used more frequently at this time. 
Association Between Arterial Stiffness and Endothelial Dysfunction 
 The association between endothelial function and arterial stiffness has not yet 
been fully elucidated, but it is believed that there is a strong association that exists 
between the two conditions. Mitchell describes the relationship like this: “these relations 
are likely to be bidirectional in that increased stiffness and excessive pressure pulsatility 
have been shown to impair endothelial function and the endothelium has been shown to 
modulate arterial properties” (214). He further suggests that there may be a detrimental 
feedback loop that exists between these two conditions, which would result in ongoing 
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decrements in both conditions over time even if only one condition is present initially. 
While this relationship has been explored, there is much to be discovered in the 
intricacies of how these two conditions function together to alter overall vascular health 
over time.  
Defining Endothelial Function 
The endothelium is the layer of tissue lining the inside of blood vessels, and it is 
the largest organ in the body. The location of the endothelium assists the vessels in 
responding to changes in the vasculature, such as BP, shear stress, and hormonal stimuli 
(96). In order to maintain homeostasis at a vascular level, the endothelium responds to 
such changes through relaxing and contracting factors (19). Some of the factors that are 
produced by the endothelium include NO, prostacyclin, endothelium-derived 
hyperpolarizing factors, and C-type natriuretic peptide (CNP) (96). Given this, the 
endothelium plays a critical role in the regulation of vascular tone, growth, inflammatory 
response, coagulation, and thrombocyte adhesion (183). Since the endothelium plays 
such an intricate role in all of these processes, imbalances at the endothelium leading to 
endothelial dysfunction can further lead to vascular exposure to vasoconstriction, 
leukocyte adherence, platelet activation, mitogenesis, pro-oxidation, thrombosis, 
impaired coagulation, vascular inflammation, and atherosclerosis (19). Therefore, proper 
functioning of the endothelium plays a critical role in vascular health. 
Measuring Endothelial Function 
There are a number of methods that have been developed to measure endothelial 
dysfunction, but the two most popular methods are ultrasound-measured flow-mediated 
dilation (FMD) and peripheral arterial tonometry (PAT), due to their non-invasive nature.  
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 FMD is the technique used most often to measure endothelial function (173). In 
short, a sphygmomanometer is placed on the forearm or above the antecubital fossa of the 
participant, where it is inflated to occlude blood flow of the brachial artery (70). 
Following ischemia, deflating the cuff results in reactive hyperemia, or increased blood 
flow (365). Reactive hyperemia causes increased shear stress, which leads to 
endothelium-dependent vasodilation (265). The diameter of the brachial artery is 
measured via ultrasound both before testing and following deflation of the cuff. The 
degree of dilation produced is indicative of NO bioavailability, which is suggestive of 
proper functioning of the endothelium (158). FMD is advantageous in that it is 
reproducible, non-invasive, fast, and safe, but several problems exist as well; 
disadvantages include high technical skill necessary of operator, operator dependence, 
extreme cooperation of the participant, and poor resolution via ultrasound images (340). 
 Another method used for assessing endothelial function is PAT, as measured by 
the Endo-PAT 2000 device. This technique is newer and may have less technical 
difficulties than those associated with FMD (277). With this method, fingertip 
plethysmography is used to measure pulse volume amplitude and detect abnormalities in 
hyperemic response (200). Briefly, plethysmographic probes are placed on the fingertips 
of index fingers, where baseline measures of pulse wave are taken. A 5-minute occlusion 
with a sphygmomanometer is ensued and then released for post-occlusion pulse wave 
data collection. Post-occlusion pulse waves are compared to pre-occlusion baseline data 
and divided by measures of the control (non-occluded) arm to determine RHI. 
Advantages to this technique include its accessibility in clinical settings, reproducibility, 
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operator independence, and non-invasiveness; however, the values determined by PAT 
may not be as predictive for all populations as those determined by other methods (277).  
Possible Associations Between Endothelial Dysfunction and Arterial Stiffness 
While the relationship between endothelial dysfunction and arterial stiffness is not 
completely understood, some similarities exist in individuals presenting with both 
conditions. Arterial stiffness and endothelial dysfunction commonly co-exist in 
individuals (249). Though the two conditions are indicative of different facets of vascular 
health, cross-talk exists between them (19). Furthermore, measures of arterial stiffness 
are significantly correlated with endothelial dysfunction (236).  
 One commonality between arterial stiffness and endothelial dysfunction is NO. 
NO plays a key part in the vascular homeostatic role of the endothelium; with endothelial 
dysfunction, the endothelium loses the ability to generate endogenous NO (321). 
Furthermore, pharmacological drugs that are given to improve endothelial function in 
humans, such as statins and angiotensin-converting enzyme inhibitors, have also 
decreased arterial stiffness, which may be due to the effect on NO (19). Another possible 
association between endothelial dysfunction and arterial stiffness is oxidative stress, 
which is present in both conditions; however, the mechanisms by which arterial stiffness, 
endothelial function, and oxidative stress may be linked are not known (258). Further 
work needs to be done to advance the understanding of potential roles that NO and 
oxidative stress may have in both conditions and how all aspects may be linked. 
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Obesity and Endothelial Dysfunction  
Obesity is clearly associated with endothelial dysfunction (304). Physiologically, 
adipose tissue can secrete hormones and pro-inflammatory cytokines, which may have 
detrimental effects on the endothelium (28). Endothelial dysfunction leads to the 
pathogenesis of cardiovascular and metabolic diseases that are associated with obesity 
(92). Endothelial dysfunction is an early marker for atherosclerosis and common to many 
CVDs (96). More specifically, endothelial dysfunction is a crucial component in the 
pathogenesis of atherosclerosis (47). Additionally, atherosclerosis and arterial stiffness 
often present together on an individual level (141). In instances of obesity, this may 
provide a link between endothelial dysfunction and arterial stiffness. Nevertheless, the 
exact relationship between obesity and endothelial dysfunction remains somewhat 
unclear. 
Nutritional Interventions to Reduce Arterial Stiffness 
 Few nutritional intervention studies have been conducted to look specifically at 
reducing arterial stiffness in overweight and obese individuals. Three nutritional 
interventions have received attention in how they might impact arterial stiffness in 
overweight and obese individuals: omega-3, isoflavone metabolite, and conjugated-
linoleic acid. In addition to the studies done on overweight and obese individuals, 
nutritional interventions have been studied in various other populations to modulate 
arterial stiffness (155, 156, 165, 167, 225, 237, 263, 306, 349, 374, 388). The 
mechanisms that underlie arterial stiffness associated with obesity have not been clearly 
elucidated, and it is unknown whether the mechanisms presenting with obesity are the 
same as mechanisms associated with increasing age or disease states. Therefore, 
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nutritional interventions that ameliorate the stiffness in one population may or may not 
translate to another population. The focus of this review will be the studies that have 
looked at nutritional interventions to improve arterial stiffness in overweight and obese 
individuals. However, some attention will also be given to research done on populations 
that were not overweight or obese. 
Omega-3 
Omega-3, a potent polyunsaturated fatty acid, has been considered in various 
clinical trials with regard to its potential effect on vascular health (174, 301). A study on 
the effects of omega-3 on the arterial compliance of overweight and obese individuals 
(BMI average = 31.7 kg/m2) showed promise for this population (305). Seventy-five 
overweight men and women were randomly placed in one of four groups: placebo 
(Sunola oil), low dose fish oil (520 mg docosahexaenoic acid (DHA) + 120 mg 
eicosapentaenoic acid (EPA) fish oil pills per day), medium dose fish oil (1040 mg DHA 
+ 240 mg EPA fish oil pills per day), or high dose fish oil (1560 DHA + 360 mg EPA 
fish oil pills per day). Each group consumed capsules for 12 weeks, and capacitive 
arterial compliance of the large and small arteries was tested by use of a proprietary 
tonometer, HDI/Pulsewave CR-2000 Cardiovascular Profiling System (Hypertension 
Diagnostics, Inc., Eagan, MN). Briefly, a BP cuff was placed on the left arm, while the 
tonometer was used at the right radial artery, allowing BP and HR to be taken at the same 
time. The tonometer, placed on the radial artery, measured decay in diastolic pressure in 
the large arteries and decay in reflective waves of the small arteries; three measures were 
taken and averaged. They found that the compliance of the large arteries was increased 
only at the highest dose of the fish oil pill but not the compliance of the small arteries. 
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Since only this high dose fish oil pill (1560 DHA + 360 mg EPA per day) improved large 
arterial compliance, they suggest that high, ~5:1 DHA/EPA fish oil doses may be able to 
improve stiffness of the arteries due to obesity. 
 Similarly, comparable results were found in a group of hypertensive, overweight 
individuals (BMI >23 kg/m2) from China. Fifty-two individuals were placed in a fish oil 
(3.0 g/day containing 540 mg EPA + 360 mg DHA) or placebo group (361). After eight 
weeks of intervention, the compliance of the large elastic arteries was measured similarly 
to the above measures (305), with a CVProfilor DO-2020 (Hypertension Diagnostics Inc., 
Eagan, MN). The compliance of the large elastic arteries, but not the small arteries, was 
improved in the fish oil group when compared to the placebo group. Interestingly, 
changes in BP were not seen in this study, suggesting that the fish oil had a direct effect 
on the compliance of the arteries independent of BP in this group of hypertensive 
subjects. In the presence of hypertension, a reduction in BP would be expected to reduce 
risk for CVD. Based on this study, even if fish oil is unable to reduce BP, it may still be 
able to protect against CVD by directly impacting the distensibility of the arteries, 
presumably through endothelial factors, as changes in inflammatory markers were not 
apparent in this study.   
 However, conflicting results were found in another study that measured the 
effects of omega-3 with or without an exercise intervention on cardiovascular risk 
factors, including large elastic artery compliance and endothelial function (140). This 
study considered overweight individuals (BMI >25 kg/m2) exhibiting at least one 
cardiovascular risk factor (HTN, elevated plasma triacylglycerols, or elevated total 
cholesterol). Eighty-one men and women were randomly assigned to a placebo group 
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(sunflower oil), placebo + exercise group (3 times/week of walking for 45 minutes at 
75% of age-predicted HR maximum), fish oil group (6.0 grams tuna fish oil/day 
containing 260 mg DHA and 60 mg EPA), or fish oil + exercise group. After a 12 week 
intervention, large elastic artery compliance, as measured by HDI/Pulsewave CR-2000 
Cardiovascular Profiler (Hypertension Diagnostics Inc., Eagan, MN) with the above 
methods (305), was not significantly changed in any of the four groups. However, fish oil 
was shown to improve endothelial function significantly over the placebo, as measured 
by FMD. Therefore, fish oil was still shown to have an effect on overall vascular health, 
though it did not seem to improve arterial compliance.  
 In the absence of obesity, EPA and DHA still show potential to improve arterial 
stiffness. In diabetics, arterial compliance was enhanced after six weeks of fish oil 
supplementation (1800 mg EPA + 360 mg DHA/day) (208), and arterial stiffness was 
reduced after a 105 week supplementation period with EPA only (1800mg/day) (212). 
After a 52 week supplementation period with EPA (1800 mg/day), individuals with 
dyslipidemia did not have an increase in arterial stiffness, as determined by PWV, but 
individuals treated with a placebo did (338). This suggests that omega-3 may also be able 
to attenuate increases in arterial stiffness that occur with time when compared to 
individuals consuming placebo. Furthermore, 12 weeks of EPA (1800 mg/day) 
supplementation in individuals with metabolic syndrome decreased PWV when 
compared to a placebo (283). In these studies, the populations of interest were neither 
obese nor overweight; however, diabetes, metabolic syndrome, and dyslipidemia are 
highly associated with obesity and arterial stiffness, which might suggest that these 
findings could translate to an obese population. Of note, two studies have looked at the 
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effects of omega-3 supplementation on healthy populations. Omega-3 supplementation 
did not have an effect on either endothelial function or arterial stiffness markers of 
healthy (mean BMI: 24.0) middle-aged men and women acutely (101) or endothelial 
function after 12 weeks of supplementation (334). While the benefits of omega-3 on 
vascular health may be present in other populations outside of obese populations, a 
healthy population does not show vascular benefit after supplementation.  
These studies related to omega-3, EPA, and DHA supplementation suggest 
potential mechanisms for their effects on arterial health. Previously, reports have 
suggested that EPA can alter the arachidonic acid system (43), which can induce 
vasodilation and improve endothelial function (338). This vasodilatory response may also 
confer advantageous modifications on a structural or functional level to reduce arterial 
stiffness (338). A favorable modification on the functional components that determine 
arterial elasticity was reported following supplementation with fish oil (361). Fish oil is 
believed to have directly affected vasoactivity through the endothelium or smooth muscle 
cells (208). Furthermore, the reduction of atherogenic cytokines from EPA could 
potentially inhibit fibrosis of the arterial wall (3, 338). EPA can modulate oxidative 
lipoproteins generated by arterial inflammation, and improvements in oxidative 
lipoproteins correlate with improvements in arterial stiffness (283). Currently, it is 
unknown whether the mechanisms that improve parameters of vascular health are the 
same between the varied groups presented in these studies. 
Based on the evidence of these randomized control trials, fish oil supplementation 
may be an effective intervention to reduce arterial stiffness. Strong support exists for fish 
oil supplementation to improve arterial stiffness in overweight individuals, with or 
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without hypertension (305, 361). Furthermore, fish oil supplementation might benefit 
individuals with diabetes (208, 212), metabolic syndrome (283), or dyslipidemia (338). 
Sample sizes were adequate to detect significance, and the duration of the studies ranged 
from 6-105 weeks of supplementation. The lowest dose that showed an effect on arterial 
stiffness was 540mg EPA + 360 DHA per day. However, only one study looked at the 
effect of fish oil on non-invasive gold standard, cfPWV (101). In this study of healthy 
individuals, omega-3 did not improve cfPWV. Therefore, further studies should look 
more specifically at the effect of fish oil on cfPWV.   
Isoflavone Metabolite 
One study has looked at the effect of isoflavone metabolite, found commonly in 
soy products, on arterial stiffness associated with obesity (233). Twenty-five overweight 
and obese men and women (mean BMI = 30.3 kg/m2) were recruited and underwent a 
five week intervention period consuming one gram per day of an isoflavone metabolite, 
trans-tetrahydrodaidzein, or a placebo, then completed a one week washout period and 
crossed over to the alternate treatment. When participants were on the isoflavone 
metabolite treatment, a 1.1 m/sec reduction in PWV, representing a 10% improvement in 
arterial stiffness after supplementation, was seen (8.80 m/s with trans-tetrahydrodaidzein 
v. 9.90 m/s with the placebo; p < 0.05). Interestingly, the treatment also caused a 
reduction in SBP, but changes in SBP and changes in PWV were not significantly 
correlated. Therefore, the reduction in arterial stiffness may be occurring separately from 
the reduction in SBP.  
 Other reports that did not target overweight or obese populations have also shown 
promise for isoflavones improving vascular health through both arterial stiffness and 
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endothelial function. Possible benefits of isoflavones on the vascular health of 
menopausal and perimenopausal women were considered in one study (234). They found 
that 5-10 weeks of supplementation with 80 mg of soy isoflavones was sufficient to 
improve systemic arterial compliance of these women. Additionally, another group 
conducted studies to look at the effects of isoflavones in men and PM women. In an 
initial study by this group, soy isoflavones improved peripheral PWV on an individual 
basis, but endothelial function was significantly worse in males after supplementing with 
isoflavones (330). However, further studies conducted in similar populations did not 
show that same negative effect on endothelial function in men; conversely, they found a 
reduction in central PWV without an effect on BP in the men and PM women (331). 
Moreover, eight weeks of soy supplementation in PM women taking tibolone for 
hormonal imbalances had no effect on arterial stiffness or endothelial function as a whole 
(339). Nevertheless, the same study found that the ability of PM women to produce 
equol, a gut bacterial metabolite of the isoflavone daidzein, had an overall effect on 
vascular health: women who were considered high equol producers had significantly 
lower arterial stiffness and endothelial dysfunction than the women who were not high 
equol producers. Nevertheless, these studies were conducted primarily in PM women, 
who are known to have significant hormonal changes that are specific to that population. 
Therefore, these results could be specific to PM women, or they could potentially be 
representative of responsiveness of arterial stiffness to isoflavones as a whole. Without 
further studies, it is difficult to speculate how isoflavones may impact arterial stiffness in 
the general population. However, there is reason to believe that isoflavones may have 
great potential to affect arterial stiffness.  
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 The effects of the isoflavone metabolite appear to occur through functional rather 
than structural changes in the arteries because of the ability of isoflavone to reduce 
arterial stiffness after a short duration (233, 331). Isoflavones may have direct effects on 
the vascular tone of the arterial wall (331), as they have been previously reported to 
inhibit endothelium independent vasoconstriction induced by norepinephrine and 
stimulate vasodilation (66). Also, in an animal model, an isoflavone metabolite reduced 
reactive oxygen species, suggesting a potential role of the antioxidant capacity of 
isoflavone to reduce the stiffness of the arteries (162). Therefore, isoflavones are believed 
to directly affect the vasoactive properties of the arteries.  
The current evidence from these randomized control trials suggests that 
isoflavone treatment may be effective at improving arterial stiffness in some populations. 
Isoflavone might be most promising for PM women (234, 330, 331), but one report did 
not show benefit of isoflavone on AIx in PM women (339). There is some evidence to 
support improvements in arterial compliance in overweight/obese men (233), healthy 
men (331), and menopausal and perimenopausal women (233). Supplementation periods 
lasted 5-12 weeks, and sample sizes were statistically adequate. Of the studies 
considering the impact of isoflavones on arterial stiffness, only one study has measured 
the effects on non-invasive gold standard, cfPWV. Thus, further studies should consider 
populations outside of PM women and measure cfPWV to understand the impact of 
isoflavones on aortic stiffness.  
Conjugated Linoleic Acid 
Improvements in arterial stiffness from conjugated linoleic acid have also been 
considered. The effect of conjugated linoleic acid in 401 overweight and obese (BMI >25 
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kg/m2) men and women, who were randomly assigned to a placebo or intervention group 
for a total of six months, was measured (309). The intervention group received 4.0 
grams/day of conjugated linoleic acid. Though prior studies in mice showed benefit of the 
conjugated linoleic acid on atherogenesis (22, 219), no change was seen in central BP or 
PWV in humans. Therefore, while conjugated linoleic acid has been one of the few 
nutritional interventions applied to improve vascular health associated with obesity, the 
research in humans to date is not encouraging. 
Evidence to support supplementation with conjugated linoleic acid is lacking 
based on this one randomized control trial considering its effect on arterial stiffness as 
measured by cfPWV (309). Because this study had an adequate sample size (401 
subjects), was 24 weeks in duration, and measured non-invasive gold standard cfPWV, 
the rigor of the study design suggests strong support for a lack of change in aortic 
stiffness due to conjugated linoleic acid in overweight but otherwise healthy individuals; 
other populations have yet to be studied. 
Other Interventions 
Various other studies have been conducted to look at arterial stiffness in 
populations that were not obese or overweight, including studies on fermented milk. 
Fermented milk has shown some possible benefit in hypertensive subjects. After 10 
weeks of supplementation with fermented milk, the ambulatory arterial stiffness index of 
a hypertensive population was decreased (156). Also, following 24 weeks of fermented 
milk supplementation, hypertensive men, but not women, saw a reduction in arterial 
stiffness, measured by AIx, and a decrease in overall reflection time (155). 
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Vitamin supplements have not shown as much potential to affect arterial stiffness 
as had originally been projected. Many vitamin studies have focused on antioxidants, 
specifically Vitamins C and E, which could theoretically affect arterial stiffness through 
their ability to reduce oxidative stress. Acute supplementation with Vitamin C (2000 mg) 
did not have an effect on the arterial stiffness of healthy individuals (165). Also, Vitamin 
E supplementation did not show an effect on arterial stiffness or arterial compliance when 
given to smokers (500 IU/day) for 152 weeks (195), to PM women (400 IU/day) for 10 
weeks (269), or to type 1 diabetics (1000 IU/day) for 12 weeks (306). Furthermore, 
Vitamins C and E in conjunction (1000 mg/day Vitamin C + 500 mg/day Vitamin E) did 
not produce any favorable change on arterial stiffness of untreated hypertensive subjects 
after eight weeks (263). Interestingly, ascorbic acid (500 mg/day) improved the arterial 
stiffness in type 2 diabetics after only four weeks of treatment (225). However, no change 
in arterial stiffness resulted in individuals with chronic heart failure after four weeks of 
supplementation with ascorbic acid (4000 mg/day) (237). Folic acid, a B vitamin that has 
also been shown to have antioxidant effects, has revealed slightly more promise than 
Vitamins C and E, but studies still do not show a reduction in aortic PWV. Longer 
supplementation periods with folic acid have not caused changes in arterial stiffness. 
Folic acid supplementation was given (15 mg/day) to chronic renal failure patients for 
173 weeks, and no improvement in arterial stiffness was seen (388). Also, no 
improvements to arterial stiffness were observed in individuals who were identified as 
siblings of those with arterial disease at 104 weeks of folic acid supplementation, which 
was combined with another B vitamin, pyridoxine (5 mg/day folic acid + 250 mg/day 
pyridoxine) (349). A shorter supplementation period with folic acid (400 µg/day) of 16 
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weeks was sufficient enough to reduce peripheral arterial stiffness, as indicated by 
brachial-knee PWV, in individuals who were diagnosed with peripheral arterial disease, 
but it did not affect central arterial stiffness (167). In men with normal or slightly 
elevated BP (SBP < 145 mmHg and DBP < 90 mmHg), three weeks of folic acid 
supplementation (5 mg/day) was sufficient to increase systemic arterial compliance, but it 
did not reduce PWV (374). Therefore, support for using vitamins as a treatment to 
improve arterial stiffness is sparse, but limited evidence exists to warrant further studies. 
While there are many nutritional interventions that have yet to be explored, the 
various randomized controlled trials presented in this review provide insight into the 
potential of several nutritional interventions to impact arterial stiffness. Some evidence 
exists to suggest that fermented milk could improve arterial stiffness, though this 
evidence is limited to hypertensive subjects (155, 156). Although sample sizes were 
adequate in the two studies considering fermented milk, and the duration of the studies 
was sufficient (10 and 24 weeks), neither study considered the effects on cfPWV. Current 
evidence does not support improvements in arterial stiffness through antioxidant 
intervention from Vitamins C and E (165, 195, 269, 306). There is minimal evidence to 
support improvements in arterial stiffness after four weeks of ascorbic acid treatment in 
type 2 diabetics (225), but further work should measure cfPWV and consider other 
populations. Some evidence has suggested that folic acid might improve arterial stiffness 
when given for supplementation periods of three weeks (374) or 16 weeks (167), but 
longer supplementation periods of 104 (349) and 173 weeks (388) have not been 
effective. Folic acid treatment may only be effective for men who are pre-hypertensive or 
have normal BP (374) or individuals with peripheral arterial disease (167). The majority 
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of studies conducted on folic acid have not considered cfPWV, but one study that did 
measure cfPWV did not see improvements after 3 weeks of supplementation (15). The 
studies that have considered fermented milk and vitamins have had adequate sample 
sizes. Therefore, some evidence exists to suggest fermented milk or folic acid as a 
treatment, minimal evidence exists to suggest ascorbic acid as a treatment, and evidence 
does not support supplementation with Vitamins C and E for improvements in arterial 
stiffness.  
Curcumin 
 Several studies have pointed to curcumin as a possible intervention for improving 
arterial stiffness, though none of these studies has focused on obese humans. Studies need 
to be conducted to understand the specific effect of curcumin on arterial stiffness due to 
obesity in a human population. To date, five main studies have looked specifically at 
curcumin as a possible intervention to improve vascular function. Of those, two studies 
were conducted in rodents, and three studies were conducted in humans. These studies 
and the possible role of curcumin in cardiovascular health, as well as overall health, will 
be discussed here.   
What is Curcumin? 
Curcumin is a naturally occurring polyphenol and the active constituent found in 
the spice turmeric, which is commonly found in Eastern countries, such as India and 
China. Within turmeric, the content of curcumin is relatively small: 3-5% (17). Though 
not as commonly found in the United States, it can be found in such foods as mustard and 
pickled radish, along with different prepared curry sauces from a grocery store or 
restaurant (299). Historically, the countries of Iran, China, and India have used turmeric 
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as an herbal remedy to treat sickness and disease (16). Though the initiation of curcumin 
as a nutritional intervention to help with various disease states or medical ailments may 
not have originally been based on research, many studies have since looked at this 
powerful nutritional component and found that it has beneficial effects throughout the 
body. 
Promise in Affecting Arterial Stiffness 
A study conducted in male C57BL/6 mice showed that curcumin has potential to 
reduce large elastic artery stiffness and attenuate endothelial dysfunction in aged mice 
(113). In this study, young (4-6 months) and old (26-28 months) mice were given a 
curcumin-supplemented chow (0.2% curcumin) or regular chow as a control for four 
weeks, corresponding with doses in humans of 0.23 g/kg day in the old group and 0.32 
g/kg day in the young group. The mice were divided accordingly: five young control 
mice, seven young curcumin mice, 10 old control mice, and 10 old curcumin mice. PWV 
was measured with Doppler probes in mice to obtain stiffness values for the aorta, and 
endothelial function was measured by looking at dose-response relationships after the 
mice were given acetylcholine (ACh), a potent vasodilator. They found curcumin had no 
effect on young mice, but it reduced aortic stiffness to levels that were not significantly 
different from young controls when given to aged mice. Furthermore, endothelial 
dysfunction was reduced in aged curcumin treated mice to a level similar to young 
controls, but there was no effect on young mice. Also, oxidative stress, as determined by 
superoxide production and nitrotyrosine, was found to be reduced to levels lower than 
young controls in old mice treated with curcumin. Decreased superoxide, in addition to 
decreased p67 subunit expression, suggested that superoxide production and dismutation 
 
45 
 
result from curcumin supplementation, affecting both pro- and antioxidant enzyme 
expression. Nitrotyrosine is a by-product of the nitration of tyrosine due to reactive 
nitrogen species, such as peroxynitrite (149). Curcumin can reduce peroxynitrite 
formation, which further reduces the degree of tyrosine nitration (335). Additionally, 
curcumin is also believed to directly scavenge free radicals (61, 113, 267). MnSOD, an 
antioxidant enzyme, levels were ameliorated in old curcumin mice to levels similar to 
young controls, though there was no effect on young mice (113). Therefore, curcumin 
may both directly reduce oxidative stress and indirectly reduce oxidative stress by 
improving antioxidant capacity of the body. Structurally, curcumin normalized collagen 
production in the old mice when compared to the old controls, while young mice saw no 
change in collagen production. Curcumin did not affect the elastin content of the aorta. 
AGEs were also normalized in old curcumin mice when compared to old controls, yet no 
effect was seen in young mice. Taken together, this study shows that curcumin was able 
to affect vascular health in mice, specifically by reducing aortic stiffness and decreasing 
endothelial dysfunction. The possible mechanisms for curcumin might be related to its 
antioxidant capacity, ability to reduce AGEs, and capacity to alter the structure of the 
vessel wall in mice.  
Another study looked at the effect of tetrahydrocurcumin (THC), a metabolite of 
curcumin, on the vascular health of hypertensive rats (230). In this study, adult male 
Sprague-Dawley rats were induced with HTN through administration of L-NAME in 
their drinking water. Then, they were divided into three groups, receiving intragastrically 
administered treatment of: polyethylene glycol (control), 50 mg/kg THC per day, or 100 
mg/kg THC per day for two weeks (corresponding with doses of THC in humans of 4.17 
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mg/kg day in the low dose group and 8.33 mg/kg day in the high dose group). Methods 
were as follows: BP was measured via tail cuff plethysmography, aortic elasticity and 
stiffness were measured with catheters inserted into the thoracic aorta to look at changes 
in volume of the aorta associated with induced changes in pressure, oxidative stress was 
measured by using an assay to assess vascular superoxide production in the carotid artery, 
and the antioxidant defense system was measured by an assay looking at glutathione 
(GSH) content in the blood of the rats. SBP was reduced with both doses of THC in these 
hypertensive rats when compared to control rats (Vehicle: 364.3 ± 23.5 µM, 50 mg/kg 
THC: 393.4 ± 25.8 µM*, 100 mg/kg THC: 449.6 ± 14.3 mmHg*; *p < 0.05). Thickness 
of the aorta, brought on by the induced HTN in these rats, was significantly reduced in 
the rats that were treated with the higher dose (100 mg/kg) but not the lower dose (50 
mg/kg) of THC. Aortic stiffness, as determined by the elastic modulus from catheter 
readings, was lowered in the rats given the higher dose of THC but not the lower dose. 
Oxidative stress, as measured by superoxide production, was reduced in the hypertensive 
rats treated with both doses of THC: 18% less in the lower dose (counts per mg dry 
weight per minute: 184.6 ± 5.6 in 50 mg/kg THC v. 224.9 ± 10.3 vehicle) and 23% less 
in the higher dose (counts per mg dry weight per minute: 173.5 ± 9.7 in 100 mg/kg THC 
v. 224.9 ± 10.3 vehicle). The antioxidant defense system, as measured by an important 
antioxidant, GSH, was reduced in hypertensive rats but was significantly higher than 
control mice after being treated with both doses of THC (Vehicle: 364.3 ± 23.5 µM, 50 
mg/kg THC: 393.4 ± 25.8 µM*, 100 mg/kg THC: 449.6 ± 14.3 mmHg*; *p < 0.05). To 
summarize, this study showed improvements in BP and aortic stiffness in hypertensive 
rats, possibly brought on by the antioxidative effect of the THC.  
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 A pilot study was conducted to look at the effect of curcumin, alone and in 
conjunction with endurance exercise, on the central arterial hemodynamics of PM women 
(322). This was a randomized, double-blind, placebo-controlled study that assigned 
women to different groups, taking into account age and BP. The study included 45 
sedentary women, randomized to each of the four groups of treatment lasting eight 
weeks: 11 placebo, 11 curcumin, 11 exercise + placebo, 12 exercise + curcumin. 
Curcumin was given as six 25 mg pills per day (150 mg total), and placebo was given as 
six similar looking starch pills at an equivalent dose. Exercise consisted of endurance 
training 3-6 days per week, initially for 25-30 minutes, 3-4 times per week but gradually 
increasing to 40-45 minutes, 4-5 days per week. The mode of exercise varied between 
supervised cycling 2-3 days per week and home-based walking. Measurements were 
taken to determine brachial and aortic BP as well as aortic stiffness from both PWV and 
AIx. Brachial SBP was decreased in the exercise + placebo group as well as the exercise 
+ curcumin group (placebo: from 119 ± 3 to 117 ± 3 mmHg, curcumin: from 120 ± 3 to 
117 ± 3 mmHg, exercise + placebo: from 117 ± 3 to 114 ± 4 mmHg*, exercise + 
curcumin: from 119 ± 2 to 114 ± 3 mmHg*; *p < 0.05; presented as SEM). Also, brachial 
DBP was reduced in the exercise + curcumin group following the eight week intervention 
(placebo: from 73 ± 3 to 71 ± 3 mmHg, curcumin: from 71 ± 2 to 70 ± 2 mmHg, exercise 
+ placebo: from 71 ± 2 to 70 ± 2 mmHg, exercise + curcumin: from 72 ± 2 to 68 ± 2 
mmHg*; *p < 0.05; presented as SEM). Additionally, the exercise + curcumin group was 
the only group that saw reductions in aortic SBP (placebo: from 114 ± 3 to 114 ± 3 
mmHg, curcumin: from 112 ± 3 to 109 ± 4 mmHg, exercise + placebo: from 113 ± 2 to 
111 ± 2 mmHg, exercise + curcumin: from 112 ± 2 to 107 ± 3 mmHg*; *p < 0.05; 
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presented as SEM) and DBP (placebo: from 73 ± 3 to 73 ± 3 mmHg, curcumin: from 72 
± 2 to 70 ± 2 mmHg, exercise + placebo: from 72 ± 2 to 70 ± 2 mmHg, exercise + 
curcumin: from 73 ± 2 to 69 ± 2 mmHg*; *p < 0.05; presented as SEM). No group 
showed differences in aortic AIx or aortic PWV. However, when AIx was corrected for 
HR (AIx75), the exercise + curcumin group showed changes that were significantly 
different from baseline (placebo: from 25.2 ± 2.5% to 30.5 ± 2.1%, curcumin: from 26.0 
± 2.3% to 28.6 ± 1.9%, exercise + placebo: from 23.3 ± 1.9% to 23.8 ± 1.0%, exercise + 
curcumin: from 23.2 ± 1.3% to 17.4 ± 3.4%*; *p < 0.05; presented as SEM). They 
suggest that exercise and curcumin may be additive in their effects, showing greater 
results combined than either of the interventions alone.  
 A similar study done by the same laboratory examined PM women (9). In this 
study, 51 PM women were placed into one of four groups: 12 placebo, 12 curcumin, 13 
curcumin + exercise, and 14 placebo + exercise. Like the above study, the intervention 
period for treatment was eight weeks, and participants were given six pills of either 
placebo or curcumin per day, amounting to 150 mg. The exercise intervention was the 
same as the previous study (322). However, in this study, different results were found as 
a response to the various interventions. Brachial SBPs (placebo: from 114 ± 4 to 114 ± 4 
mmHg, curcumin: from 123 ± 5 to 119 ± 4 mmHg*, exercise + placebo: from 112 ± 3 to 
108 ± 3 mmHg*, exercise + curcumin: from 118 ± 4 to 113 ± 4 mmHg*; *p < 0.05; 
presented as SEM) and carotid SBPs (placebo: from 103 ± 3 to 104 ± 3 mmHg, 
curcumin: from 112 ± 5 to 108 ± 4 mmHg*, exercise + placebo: from 103 ± 3 to 99 ± 3 
mmHg*, exercise + curcumin: from 107 ± 4 to 102 ± 4 mmHg*; *p < 0.05; presented as 
SEM) were lower in the curcumin group, curcumin + exercise group, and the exercise + 
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placebo group after eight weeks of the intervention. In the curcumin + exercise group, 
brachial DBP was lower than initial values but not in any other group (placebo: from 71 ± 
3 to 71 ± 3 mmHg, curcumin: from 72 ± 4 to 69 ± 3 mmHg, exercise + placebo: from 69 
± 2 to 68 ± 2 mmHg, exercise + curcumin: from 71 ± 3 to 67 ± 3 mmHg*; *p < 0.05; 
presented as SEM). Carotid arterial compliance was higher following eight weeks of 
intervention with curcumin, exercise + placebo, or exercise + curcumin, but the 
percentage of change was only significant in the exercise + curcumin group. The authors 
concluded that curcumin, as a treatment, gave similar benefits to central arterial 
compliance as those of aerobic exercise alone (10.1 ± 4.5% v. 10.0 ± 3.6%). 
Additionally, the combination of exercise and curcumin led to significantly greater 
increases in arterial compliance, suggesting that the combination of the two interventions 
could be additive.  
A final study done by the same lab looked at the response of vascular endothelial 
function of PM women to curcumin (8). In this study, 32 PM women were placed into 
one of three groups: 10 placebo, 11 curcumin, and 12 exercise. The curcumin and 
exercise interventions were the same as those outlined in the previous studies and also 
lasted eight weeks (9, 322). After eight weeks, brachial SBP was lower in the curcumin 
and exercise groups than the placebo group (placebo: from 112 ± 12 to 113 ± 11 mmHg, 
curcumin: from 122 ± 17 to 116 ± 15 mmHg*, exercise: from 112 ± 10 to 107 ± 10 
mmHg*; *p < 0.05). Endothelial function, as measured by FMD, was also lower in both 
the curcumin and exercise groups than the placebo (values not reported). They concluded 
that curcumin produced similar benefits on vascular endothelial function to that of 
aerobic exercise. 
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Therapeutic Effects of Curcumin 
Curcumin shows great therapeutic promise and has been shown to improve 
conditions related to varying disease states (5, 11, 18, 41, 65, 161, 176, 190, 196). Most 
notably, curcumin has established anti-inflammatory properties (4, 11, 32, 62, 161). 
Because inflammation is a major component of many disease states, the ability of 
curcumin to impact this aspect may afford it great potential in ameliorating the conditions 
of many diseases. Curcumin’s effects on inflammation are due to its ability to inhibit 
NFĸB signaling, which regulates various inflammatory pathways (333). Curcumin can 
modulate NFĸB signaling by inhibiting the activation of NFĸB and its translocation into 
the nucleus (126, 303). The ability to affect NFĸB will specifically reduce downstream 
inflammatory cytokines TNF-α, IL-1β, and IL-6 in the aorta and adipocytes (122, 126). 
Furthermore, curcumin reduces macrophage infiltration, activation, and accumulation 
into adipose tissue and may thereby have a more direct influence on inflammatory 
mediators (362, 379). 
Moreover, curcumin has documented powerful antioxidant activity (7). Oxidative 
stress is also a major component of various disease states, increasing the ability of 
curcumin to have beneficial effects in diseased individuals (241). Curcumin can both 
decrease oxidative stress and improve antioxidant activity within the body (103, 113, 
169, 209, 227, 266). Oxidative stress is directly impacted by the ability of curcumin to 
scavenge free radicals (209). Additionally, curcumin can impact endogenous antioxidant 
systems: superoxide dismutase and glutathione peroxidase (24, 113). Gluthathione 
peroxidase and superoxide dismutase are considered two of the most important enzymes 
of the antioxidant defense system in the cell and reduce oxidative damage due to free 
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radicals within the cell (261). Therefore, curcumin can directly and indirectly influence 
oxidative stress.  
The anti-carcinogenic effects of curcumin have been well-studied (18). Curcumin 
has been shown to inhibit the growth of tumors in the blood, brain, breast, gastrointestinal 
system, head, neck, liver, pancreas, colon, prostate, ovary, and skin (18). It is believed 
that curcumin has these potent effects based on anti-inflammatory, anti-oxidative, 
apoptotic, and anti-angiogenic effects in the body (41). The promise of curcumin in 
rodent models is present in studies that involve prevention against neurodegenerative 
diseases such as Alzheimer’s and Parkinson’s diseases (241). Curcumin may also have 
the ability to affect skin conditions, such as psoriasis (177), or even general wound 
healing (196). Furthermore, positive outcomes with curcumin in diabetic rodents have 
occurred primarily through its ability to reduce hyperglycemia (124) and 
hypercholesterolemia (50, 311). While evidence is not as well-established, curcumin has 
also shown promise in affecting the respiratory system, the urinary system, the 
musculoskeletal system, and the reproductive systems of both males and females (241). 
Few studies have even pointed to curcumin’s beneficial antimicrobial effects, 
enhancement of immunity, and gastrointestinal effects (10). Benefits of curcumin on the 
cardiovascular system will be discussed below. Undoubtedly, curcumin has been shown 
to have positive effects on several systems in the body to varying degrees. 
Effects on Cardiovascular Disease 
Very few studies have looked at the effects of curcumin on the cardiovascular 
health of humans, but a few have studied aspects of CVD. One study showed that 
curcumin increased serum HDL levels and decreased serum LDL levels of patients with 
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atherosclerosis after four weeks of treatment at 20 mg per day (50). Another study with a 
much shorter intervention period of seven days, yet a much higher dose of curcumin (500 
mg), found: increases in serum HDL, decreases in total serum cholesterol, and decreases 
in serum lipid peroxides (311). A final study showed that curcumin reduced the 
proliferative activity associated with atherosclerosis in human peripheral blood 
mononuclear cells and vascular smooth muscle cells in vitro (148). Furthermore, rodent 
studies have shown that curcumin has been linked to: protecting the myocardium from 
ischemic insult (312), reducing cardiotoxicity (351), providing protective effects on the 
cardiovascular system when diabetes is present (103), showing protective effects against 
myocardial infarction (239), and providing preventative effects against cardiac heart 
failure (223). Furthermore, the anti-proliferative and anti-inflammatory nature of 
curcumin may contribute to curcumin’s ability to have a protective role in CVD. 
Curcumin proved protective against endothelial dysfunction in porcine coronary arteries 
(267). Based on this evidence, there is reason to believe that curcumin could be a potent 
nutritional component for improving and protecting overall cardiovascular health.   
Effects on Obesity 
In addition to having specific effects on the above systems of the body, curcumin 
has been shown to have favorable outcomes on obesity. Based on curcumin’s anti-
hyperlipidemic effect described above, curcumin is believed to possibly ameliorate fatty 
liver disease (11) and has been shown to present some benefit to fatty liver disease in 
hamsters (152). Also, insulin sensitivity, which is often found in obese individuals, can 
be improved through the anti-hyperglycemic effect of curcumin (11). Improvements in 
diabetes may be relevant for obese individuals, as obesity contributes to the development 
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of type 2 diabetes (252, 290). Inflammation plays a major role in obesity, so the ability to 
reduce inflammation through inflammatory mediators in obese individuals may be 
pivotal, especially as it relates to CVD and insulin resistance (11). Additionally, obese 
individuals may experience a considerable amount of oxidative stress, which has been 
shown to improve with curcumin (345), though not in an obese population specifically. 
Healthy subjects had increased postprandial plasma insulin levels as a result of curcumin 
(366). Therefore, curcumin could potentially protect obese individuals from diabetes 
through effects on oxidative stress and insulin (11). Furthermore, in a clinical trial of 
diabetics, curcumin improved endothelial function, reduced oxidative stress, and 
decreased inflammatory markers (343). One study even showed that curcumin was able 
to increase the basal metabolic rate and induce weight loss in high-fat-fed mice (362). 
Weight loss has been shown to improve arterial stiffness in overweight and obese 
individuals (68). Many of the studies suggesting favorable effects of curcumin on obesity 
have been conducted in mice (152, 248, 362), and clinical studies should consider 
whether these same findings would translate into human studies. Therefore, curcumin 
could increase function of the cardiovascular systems of overweight and obese 
individuals, but there is a clear need for clinical trials to examine the effects of curcumin 
on obesity.  
Absorption of Curcumin 
While curcumin has favorable therapeutic effects, curcumin has poor 
bioavailability in humans (241). Reduced bioavailability is believed to be attributed to 
poor absorption, rapid metabolism, and rapid elimination of curcumin (4). Therefore, 
methods to increase the bioavailability of curcumin in humans are necessary.  
 
54 
 
Fenugreek to Increase Absorption of Curcumin 
 One formulation that has been shown to increase the absorption of curcumin is the 
soluble fiber from fenugreek when infused with curcumin. Fenugreek is a naturally-
occurring annual plant from India and North Africa and has been identified as one of the 
oldest medicinal plants (31). Fenugreek seeds are composed of 50% fiber, found in the 
forms of 30% soluble fiber and 20% insoluble fiber (31). Fenugreek has been shown to 
lower fasting serum glucose levels in type 2 diabetics (129, 291) and type 1 diabetics 
(292). Moreover, fenugreek is known to lower LDL and triglyceride levels in 
hyperlipidemic adults (293) as well as total cholesterol, LDL, and triglyceride levels 
while increasing HDL levels in type 2 diabetics (294, 295). While curcumin and 
fenugreek as a combination have been studied to look at fenugreek’s ability to improve 
absorption, their effects on cardiovascular health have not been studied. Fenugreek is 
well-tolerated, showing little to no clinically significant adverse side effects, and should 
be considered a safe addition to curcumin (31, 175).  
 In one study, the effectiveness of fenugreek as an additive to increase absorption 
was tested in both rats and humans (175). To enhance absorption, the soluble fiber 
portion of fenugreek was extracted and curcumin was added to it. Rats were divided into 
two groups of eight, receiving curcumin in its natural state or curcumin impregnated into 
the soluble fiber of fenugreek. They found that the group consuming fenugreek with 
curcumin absorbed the curcumin 20 times better than the group consuming curcumin 
alone. Furthermore, in humans, two separate doses of curcumin were added to the 
fenugreek fiber: 250 mg and 1500 mg. Eight healthy males aged 25-45 years were given 
each of these two doses as well as one gram of unformulated curcumin at different time 
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points, separated by one week washout periods. Thus, they served as their own controls. 
Compared to the unformulated curcumin, the fenugreek + curcumin supplements were 
absorbed 12.9 times higher in the smaller dose and 15.8 times higher in the larger dose. 
Therefore, they concluded that fenugreek fiber was effective at enhancing absorption, but 
they also noted that there was a dose dependency. This suggests that fenugreek is a novel 
way to increase the absorption of curcumin and could prove to be a powerful substance to 
increase benefits seen through the consumption of curcumin. The authors report that 
fenugreek was able to improve absorption of curcumin through the improved 
hydrophobic-hydrophilic balance, which could allow for a prolonged release of colloidal 
curcumin throughout the digestive tract. Whereas unformulated curcumin is rapidly 
metabolized and degraded by enzymes of the upper gastrointestinal tract, the combination 
of fenugreek fiber and curcumin creates a stable colloid that swells rather than degrades 
in the presence of physiological pHs simulating stomach and colonic conditions. This 
could increase absorption, decrease the rate of metabolism, and decrease the rate of 
elimination characteristic of unformulated curcumin. Studies including this combination 
should be conducted to look at the possible benefits in humans when absorption of 
curcumin is increased.  
Conclusion 
 CVDs are the leading cause of death worldwide. Large elastic artery stiffness 
serves to be a pronounced, independent predictor of CVD and serves as a better predictor 
than traditional markers, such as resting BP. Therefore, interest in improving overall 
vascular health, as monitored by measures of large elastic artery stiffness, should be of 
great concern. While many studies have focused on how to reduce arterial stiffness in 
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aged populations, few have looked at a specific population that is prevalent and still on 
the rise – obese individuals. More studies need to be done to expose novel interventions 
for reducing arterial stiffness in overweight and obese individuals. Some exercise and 
nutritional interventions have been studied in the past few years, but curcumin requires 
further study to elucidate potential effects on the cardiovascular system. Curcumin, a 
powerful nutritional constituent in reducing inflammation, oxidative stress, and even 
tumors, needs to be looked at for specific effects that it can have on overall 
cardiovascular health. While bioavailability can be a problem in humans, adding 
fenugreek to curcumin can enhance absorption dramatically. Studies to look at curcumin 
with enhanced bioavailability from fenugreek to ameliorate overall cardiovascular health 
in obese individuals could be of great benefit to this increasing population.  
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CHAPTER III 
METHODS 
Experimental design 
The purpose of this study was to evaluate the effectiveness of curcumin to 
improve arterial health in young (18-35 years old), obese men. The experimental design 
included a 12-week longitudinal study with four time points: 0 weeks (pre-intervention), 
4 weeks, 8 weeks, and 12 weeks (post-intervention). The timeline of the visits along with 
the associated measures that were assessed at each visit are shown in Figure 3-1. This 
study was a randomized placebo-controlled study, with the investigator responsible for 
taking measures and the subjects unaware of the groupings of the subjects. After 
volunteers were screened for eligibility, qualified subjects were matched based on BMI 
and randomized by a random numbers table into treatment or control groups. The 
intervention consisted of 12 weeks of curcumin (with added fenugreek, to enhance 
absorption). The control intervention consisted of 12 weeks of fenugreek, serving as the 
placebo. To monitor changes in cardiovascular health over time, arterial stiffness, 
endothelial function, BP, HR, and inflammatory cytokines were measured throughout the 
study. All testing was performed after a minimum of a four-hour fast including no 
caffeine. 
Subjects 
 Subjects were recruited via local advertisement and word of mouth at the 
University of Kentucky. Healthy males aged 18-35 years with BMI ≥ 30 kg/m2 were 
recruited for this study. The subjects were pre-screened via e-mail before their initial visit 
to ensure that BMI, age, and medical history were in conjunction with inclusion criteria.  
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Figure 3-1. Timeline of visits and associated measures 
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The subjects were continuously enrolled in the study and matched based on BMI, then 
randomly assigned to the curcumin (intervention) group or the placebo (control) group. 
When a BMI-matched counterpart was identified, he was assigned to the group opposite 
of his pair. Prior to participation at their first visit, written consent was obtained from 
each participant as required by the University of Kentucky Institutional Review Board. 
Following consent, all subjects filled out a health history questionnaire, self-reporting 
medical history for determination of eligibility, and completed a resting 12-lead EKG. 
Alcohol dependence and abuse was determined by the CAGE Substance Abuse 
Screening Tool (99), with a total score of two or higher considered clinically significant.  
 Inclusion Criteria: Male, 18-35 years of age, BMI ≥ 30 kg/m2 
 Exclusion Criteria: HTN ( > 140 SBP or > 90 DBP at rest), medication, 
CVD, diabetes mellitus, pulmonary disease, previous myocardial 
infarction, renal disease, HIV, alcohol dependence or abuse; smoking 
While age is the predominant predictor of arterial stiffness (229), age was not the 
focus of this study, as the impact of curcumin on vascular health with aging has been 
studied previously (8, 9, 113, 322). Previous work considering arterial stiffness in young 
individuals has selected individuals 18-35 years of age (35, 106, 131, 147, 151, 181); 
thus, these cut offs were also used for this study. Also, the impact of curcumin on the 
arterial stiffness in women has been studied (322), and previous work has suggested that 
sex differences might be specific to hormonal differences between women (6). The 
discrepancy between the sexes may also be amplified with obesity (242). To eliminate the 
discrepancy that exists in arterial stiffness between the sexes and elucidate whether 
curcumin will have an effect on arterial stiffness with obesity, men were exclusively 
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chosen for this study. Inclusion and exclusion criteria were specified to eliminate other 
risk factors for arterial stiffness so that the current work could focus on obesity-related 
stiffness. It is not known whether the mechanisms that underlie arterial stiffness due to 
different conditions may be the same. The effects of curcumin may not uniformly impact 
arterial stiffness due to these varying conditions, so consideration was given to select a 
relatively homogenous group of young obese men. Increased arterial stiffness has been 
associated with HTN, CVD, diabetes, MI, renal disease, HIV, smoking, and excessive 
alcohol intake (40, 119, 201, 207, 211, 285, 288, 300, 324). Evidence suggests that 
curcumin may interact with medication (21), but specific interactions with drugs are not 
currently known, so individuals on medication were not accepted into this study. 
Upon enrollment in the study, participants were instructed not to change any 
major lifestyle factors, including physical activity and nutritional habits, as these factors 
have been shown to influence arterial health (245, 255, 329).  
Intervention 
Both groups underwent a 12-week intervention period with supplementation. 
Previous randomized control trials to assess the efficacy of nutritional interventions to 
improve arterial stiffness have used a 12-week intervention (261, 283, 305, 306, 330, 
334, 341). Other studies have found that a period as short as a four week intervention was 
sufficient to produce favorable changes in cfPWV, but it is not known whether this might 
have been specific to the intervention (136, 337).  In randomized controlled trials 
specifically considering curcumin for vascular health, eight weeks was sufficient to 
produce favorable changes in arterial compliance, SBP, and FMD (8, 9, 322). Therefore, 
a 12 week intervention was hypothesized to be sufficient to detect favorable changes in 
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arterial stiffness, and to identify the time course of change every four weeks, subjects 
reported at four and eight weeks of study duration. Due to known problems with the 
absorption of curcumin in humans (17), the intervention group received pills that 
included 1.0 gram of curcumin formulated with 60% soluble fiber from fenugreek seeds, 
obtained from Akay Flavours & Aromatics Ltd., to enhance the absorption of curcumin. 
This formulation has been shown to increase bioavailability up to 15.8 times when 
compared to administering curcumin alone in humans (175). The placebo group was 
given a pill that looked identical in size and shape to the intervention pill, formulated 
with the same amount of fenugreek as found in the intervention pill to account for any 
potential benefits on arterial stiffness from the fenugreek. Placebo supplements were also 
obtained from Akay Flavours & Aromatics Ltd. All pills were administered in a four-
week block pill box with weeks and days indicated to enhance compliance in the study. 
At each visit, subjects received 32 pills of the intervention or placebo (1 pill/day + 4 extra 
pills), ensuring contact with our research team approximately every four weeks. Each 
subject was encouraged to take pills at the same time every day. Additionally, subjects 
were required to record pill consumption dates to further enhance compliance.  
Procedures 
Anthropometric and Body Composition Measures 
 Measurements for height, body mass, hip circumference, waist circumference, 
and body composition were collected for each participant at each of the four visits. 
Subjects wore light-weight clothing and no shoes for the height, weight, hip 
circumference, and waist circumference measures. Height was determined using a wall-
mounted stadiometer (PORTROD; Health-o-meter, Alsip, IL) and was measured to the 
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nearest 0.1 centimeter. Subjects stood with head, back, and heels against the wall for the 
height measurement. Body mass was measured to the nearest 0.01 kilogram using a 
calibrated electronic scale (DI-10; DIGU, Rice Lake, WI). Hip and waist circumference 
measures were determined using a spring-loaded fiberglass anthropometric tape (Gulick 
Deluxe; Baseline Evaluation Instruments, White Plains, NY). Waist and hip 
circumferences were taken in triplicate, alternating between the two sites, and measured 
to the nearest 0.1 cm for each subject. Waist circumference was measured at the level of 
the umbilicus, and hip circumference was measured at the largest circumference around 
the gluteal muscles, as indicated by the NIH in the Multi-Ethnic Study of Atherosclerosis 
(MESA) (45, 67, 310). The coefficient of variation for repeated measures was 0.4% for 
waist circumference measures and 0.8% for hip circumference measures.  
Body Composition Measures 
Body composition measures were taken with a tetrapolar bioelectrical impedance 
analyzer. Height and weight measurements taken in the laboratory were used to input into 
the Bioelectrical Impedance Analyzer (Multi-frequency Quadscan 4000 Bioelectrical 
Impedance Analyzer; Bodystat Ltd., Douglas, United Kingdom). Subjects laid supine on 
a non-conducting surface, and electrodes were placed on the right side of the body at four 
locations: (1) bisecting the head of the ulna of the right wrist, (2) at the base of the 
metacarpal-phalangeal joint on the right hand, (3) bisecting the medial and lateral 
malleoli of the right foot, and (4) at the base of the metacarpal-phalangeal joint of the 
right foot. Multiple frequencies (5, 50, 100, and 200 KHz) were used to determine 
impedance, and manufacturer proprietary equations from the machine determined percent 
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fat, fat mass, and fat-free mass. When compared to total body DXA scans, the body fat 
equation has a reported validity of r = 0.88 (323). 
Pulse Wave Velocity 
Large elastic artery stiffness was assessed by measuring cfPWV, which is 
considered the non-invasive gold standard (186). In trained testers, the Sphygmocor 
system (Sphygmocor; AtCor Medical, Sydney, Australia) shows good reproducibility 
within days and between days, but it should be calculated for the specific tester (332). In 
this study, the repeatability of measurements for the trained tester was determined as a 
between day coefficient of variation for repeated measures of 7.03% and a within day 
coefficient of variation for repeated measures of 7.08%. Before pulse wave measures 
could be obtained, subjects were required to lay in a rested supine position for 10 minutes 
in a quiet thermoneutral room. To determine the best sites for measuring arterial pressure 
at the carotid and femoral pulse, the two sites were identified and marked for repeated 
measurements. Distance from the carotid to femoral arteries was measured with a flexible 
fiberglass measuring tape, and the value was recorded to the nearest millimeter. Blood 
pressure measurements, taken at the brachial artery, were recorded for the cfPWV 
measures; BP measurements, taken in a rested supine position, were also assessed as a 
secondary outcome. Then, the subject was prepared with a 3-lead EKG. If chest hair 
obstructed EKG placement, hair was shaved, and the subject was prepped with an alcohol 
pad to remove skin oils. A non-invasive tonometer was used at the carotid and femoral 
arteries to consecutively record pulse waves, while the integrated EKG recorded transit 
times. cfPWV was determined using a simple calculation by the computer system: 
distance traveled / transit time of the pulse wave. Distance traveled was taken directly 
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from the distance measured between the carotid and femoral sites described earlier, while 
the transit time was calculated as the delay in onset of the pulse wave from the carotid to 
femoral sites (the device uses a foot-to-foot method from the carotid to femoral sites), as 
calculated from the images of the pulse wave and EKG measurements. cfPWV 
measurements were calculated automatically by the Sphygmocor system and presented in 
meters per second. Three measures were taken and averaged to determine cfPWV. A 
single, trained tester took all of the cfPWV measures for all subjects in the study.  
Pulse Wave Analysis 
 The same Sphygmocor system (Sphygmocor; AtCor Medical, Sydney, Australia) 
was used for pulse wave analysis (PWA). The tonometer was placed at the radial artery 
and the signal that was produced was used in conjunction with the BP measurement in a 
validated transfer function (63) to determine central BP and AIx.  
Endothelial Health 
To measure endothelial health, RHI as produced by the Endo-PAT 2000 (Itamar 
Medical, Ltd., Caesarea, Israel) was determined, and all procedures were in accordance 
with the manufacturer’s specifications (150). Endo-PAT 2000 has been validated as an 
independent predictor of late CV adverse events (277). The device shows strong 
repeatability for two PAT tests conducted on 20 healthy volunteers taken an average 0f 
19.5 days apart (intra-class correlations for RHI = 0.74) (203). From this device, arterial 
pulse waves of the peripheral arteries were used to determine endothelial function via 
finger probe plethysmography. An additional resting BP measure was taken from each 
participant with a standard BP cuff; BP measurements were taken from a supine position 
with arms rested at the sides of the participant while in a relaxed position. Then, finger 
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probes were place on the index finger on both hands of the individual, and individuals 
were instructed to remain still and relax. The finger cuffs of the Endo-PAT machine were 
inflated and five minutes of baseline data were collected from the individual after the 
probes were inflated. After baseline data were assessed, the BP cuff was inflated to 200 
mmHg to occlude the brachial artery. Five minutes of data were collected from the finger 
probes during occlusion, after which the cuff was deflated. Following occlusion, an 
additional five minutes of post-occlusion data were collected to determine RHI. The 
Endo-PAT 2000 calculated RHI by determining the post- to pre-occlusion ratio of the test 
arm divided by the post- to pre-occlusion ratio of the control arm.  
Dietary History Questionnaire 
 To monitor dietary changes throughout the study, a food frequency questionnaire 
(FFQ) known as the Dietary History Questionnaire (DHQ) (88) was given at the first and 
fourth visit, with a specified food database for the American population (84). The online 
questionnaire was administered at the time of the visit and was used in conjunction with 
Diet*Calc software for analysis (87). Questions provided by the DHQ were based on the 
one month period prior to assessment; therefore, the one month time period before the 
first and fourth visits were captured by the DHQ. The DHQ was chosen for its simplicity, 
ability to assess dietary changes over a four week period, accessibility, and validity (319, 
336). Of the four versions available, DHQ-II based on dietary consumption within the 
past month, including questions about portion sizes, was utilized. The DHQ is freely 
available to researchers, clinicians, and teachers, and was developed by staff at the Risk 
Factor Assessment Branch (RFAB) of the National Cancer Institute (NCI) at the National 
Institutes of Health (NIH). The food database includes 134 food items and eight dietary 
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supplement questions based on national dietary data from the National Health and 
Nutritional Examination Surveys (NHANES) from 2001-2002, 2003-2004, and 2005-
2006 (86). The DHQ was validated in 1992 and 1995 (319, 336).  
Dietary intake assessment representing one month of dietary habits prior to the 
visit was analyzed by the Diet*Calc software (87). Total HEI scores are based on 
conformance to Dietary Guidelines for Americans (342) on a 100 point scale. Each 
component of the HEI score is scored based on a 5-20 point scoring system, where higher 
scores indicate higher conformance to dietary guidelines. Of the 12 categories composing 
the total HEI score, six categories are on a 5-point scale: total fruit, whole fruit, total 
vegetables, greens and beans, total protein food, and seafood and plant proteins. Five 
categories are on a 10-point scale: whole grains, dairy, fatty acids, refined grains, and 
sodium. One category is on a 20-point scale: empty calories. 
Blood Sampling 
Blood draws amounting to approximately 40 mL were taken from the antecubital 
vein by trained staff at the University of Kentucky’s Center for Clinical and Translational 
Sciences (CCTS). Two blood draws were taken per subject, with whole blood samples 
collected at the first and fourth visits. Samples were centrifuged, processed, and frozen at 
-80ºC in aliquots of serum and plasma by nurses in the CCTS until all samples were 
collected for all subjects. Extracted plasma was assessed by a lab technician in the CCTS 
after all samples were collected using the V-PLEX Proinflammatory Panel 1 (human) Kit 
by Meso Scale, a multi-spot assay system, with EDTA. Samples were analyzed for 
several inflammatory cytokines from this pro-inflammatory panel, including IFN-γ, IL-
1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and TNF-α. Briefly, this technique 
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employed a pre-coated plate with antibodies to capture the 10 inflammatory cytokines on 
specific sites. A sandwich immunoassay was used, whereby the sample and an antibody-
containing solution were added to the plate. The capture antibodies on the plate were 
bound to the analyte of interest, and the analyte recruited detection antibodies. A buffer 
was added to the plate, and detection antibodies allowed for quantification of 
concentrations based on the intensity of the light that was emitted. 
Statistical Analysis 
To analyze the data presented in this study, we used SAS software, Version 9.4 of 
the SAS System Copyright © 2015 (SAS System for Windows; SAS Institute Inc., Cary, 
NC). A p-value of ≤ 0.05 was considered statistically significant. Descriptive 
characteristics of the subjects are presented as means and standard deviations. A linear 
regression model with mixed effects was employed to assess change scores between 
baseline and subsequent visits with the independent variables: treatment groups (2 levels: 
curcumin v. placebo) as a between subjects variable and time points (2 or 4 levels: pre v. 
post or 0, 4, 8, and 12 weeks) as a within subjects variable. Random effects were included 
to capture correlations among the observations within a pairing. A similar model was 
used to analyze the two levels of responsiveness (responders v. non-responders) in the 
curcumin-treated group, except that the random effects for pairing were no longer 
considered in the model. Baseline data were analyzed with paired samples t-tests to 
compare means between the intervention and placebo groups and independent samples t-
tests for the responders and non-responders. Microsoft Excel was used to determine 
simple linear regression models for the primary and secondary outcomes at baseline. A 
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multiple regression analysis was employed using forward selection from the SAS REG 
procedure with SLE = 0.05 inclusion criteria for the primary outcome at baseline. 
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CHAPTER IV 
RESULTS 
Subjects 
 This study enrolled a total of 22 obese (BMI ≥ 30 kg/m2) yet otherwise healthy 
young (18-35 year old) males. All 22 subjects completed the 12 week protocol, resulting 
in 100% retention in the study.  
Baseline characteristics for body composition, arterial stiffness, RHI, and 
inflammatory cytokines of the curcumin and placebo groups can be found in Table 4-1. 
There were no differences in baseline subject characteristics between the curcumin and 
placebo groups, though concentrations of pro-inflammatory cytokine IL-2 and anti-
inflammatory cytokine IL-13 in the plasma were trending (p = 0.052 and p = 0.075, 
respectively). 
Compliance to supplementation was self-reported via pill log sheets every four 
weeks. Overall, compliance was 96.74% for both groups. There was no difference in 
compliance between the placebo and curcumin groups (98.02% v. 95.42%, respectively; 
p = 0.251). No adverse side effects from curcumin or placebo supplements were reported.  
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Table 4-1. Baseline characteristics of the curcumin and placebo groups 
  Curcumin (n = 11) Placebo (n = 11) p-value 
Age (years) 25.91 ± 4.46 26.64 ± 4.06 0.648 
Height (cm) 178.26 ± 6.50 175.60 ± 5.15 0.310 
Weight (kg) 106.13 ± 15.81 102.34 ± 1.60 0.196 
Body Mass Index (kg/m2) 33.29 ± 3.69 33.18 ± 3.38 0.644 
Hip circumference (cm) 114.47 ± 8.41 112.80 ± 5.87 0.577 
Waist circumference (cm) 108.93 ± 11.99 106.27 ± 10.37 0.187 
Body fat (%) 27.22 ± 4.90 27.18 ± 5.46 0.972 
Fat mass (kg) 29.46 ± 9.80 28.32 ± 9.22 0.457 
Fat-free mass (kg) 76.66 ± 7.28 73.97 ± 4.07 0.140 
Waist:hip ratio 0.95 ± 0.05 0.94 ± 0.06 0.442 
Waist:height ratio 0.61 ± 0.07 0.61 ± 0.06 0.711 
Brachial SBP (mmHg) 123.64 ± 8.48 124.91 ± 8.96 0.596 
Brachial DBP (mmHg) 77.09 ± 9.01 81.82 ± 5.40 0.191 
Brachial PP (mmHg) 46.55 ± 10.20 43.09 ± 6.41 0.797 
Brachial MAP (mmHg) 92.61 ± 7.41 96.18 ± 6.09 0.221 
Central SBP (mmHg) 105.64 ± 7.10 109.18 ± 6.10 0.197 
Central DBP (mmHg) 77.64 ± 8.99 82.18 ± 5.62 0.201 
Central PP (mmHg) 28.00 ± 6.18 27.00 ± 4.86 0.693 
Central MAP (mmHg) 86.97 ± 7.89 91.18 ± 5.31 0.172 
Aortic AIx (%) -0.64 ± 11.91 7.55 ± 10.14 0.141 
Aortic AIx75 (%) -9.45 ± 13.54 -5.00 ± 10.54 0.438 
Resting HR (bpm) 57.90 ± 6.79 56.64 ± 4.82 0.757 
cfPWV (m/s) 6.27 ± 0.85 6.31 ± 0.99 0.369 
Reactive Hyperemia Index 2.02 ± 0.50b 2.08 ± 0.53 0.829 
IFN-γ (pg/mL) 2.94 ± 0.94b 4.51 ± 0.66a 0.144 
IL-2 (pg/mL) 0.17 ± 0.13 b 0.45 ± 0.42 a 0.052 
IL-4 (pg/mL) 0.07 ± 0.05 b 0.12 ± 0.10 a 0.301 
IL-6 (pg/mL) 0.77 ± 0.33 b 0.62 ± 0.27 a 0.279 
IL-8 (pg/mL) 3.71 ± 0.72 b 3.48 ± 0.72 a 0.631 
IL-10 (pg/mL) 0.29 ± 0.11 b 0.45 ± 0.32 a 0.217 
IL-12 p70 (pg/mL) 0.32 ± 0.22 b 0.50 ± 0.38 a 0.359 
IL-13 (pg/mL) 3.92 ± 3.50 b 9.00 ± 3.37 a 0.075 
TNF-α (pg/mL) 1.76 ± 0.49 b 1.71 ± 0.45 a 0.711 
an = 9; bn = 10; n.d. = not detectable; *p < 0.05, between groups. Values are means ± SD. 
SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; PP = Pulse Pressure; 
MAP = Mean Arterial Pressure; HR = Heart Rate; cfPWV = carotid-femoral Pulse Wave 
Velocity; AIx = Augmentation Index; AIx75 = Augmentation Index Corrected for Heart 
Rate of 75; IFN = Interferon; IL = Interleukin; TNF = Tumor Necrosis Factor 
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Primary Variable of Interest 
Pulse Wave Velocity 
 There was no difference in cfPWV between groups at baseline (Table 4-1). The 
overall average cfPWV measures for subjects in this study was 6.29 ± 0.88 m/s at 
baseline, and the group averages were 6.27 ± 0.85 m/s in the curcumin group compared 
to 6.31 ± 0.99 m/s in the placebo group at baseline (p = 0.369, between groups 
comparison). Changes throughout the 12 week intervention in cfPWV can be seen in 
Figure 4-1. Differences after the 12 week intervention were not seen in the curcumin 
compared to placebo groups in cfPWV (p = 0.428, interaction of group by time).  
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Figure 4-1. Changes in cfPWV in curcumin and placebo groups throughout the intervention 
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Responders and non-responders to the curcumin treatment 
 Further exploration of the responsiveness of individuals to the curcumin treatment 
revealed that some individuals responded to the curcumin treatment, while others did not. 
Curcumin-supplemented men were grouped into “responders” and “non-responders” 
based on their course of response to curcumin treatment. Responders were defined as 
those individuals who saw reductions in cfPWV (n = 6), while non-responders were those 
that did not (n = 5). Characteristics of responders and non-responders to the curcumin 
treatment can be found in Table 4-2. It was found that individuals with higher cfPWV 
measures at baseline responded to the treatment whereas individuals with lower cfPWV 
measures at baseline did not respond to the treatment (6.81 ± 0.83 m/s v. 5.84 ± 0.41 m/s, 
p = 0.045). The differences between cfPWV measures at baseline in the responders and 
non-responders can be seen in Figure 4-2. Furthermore, differences were observed 
between the responders and non-responders in the waist:height ratio (0.58 ± 0.03 v. 0.65 
± 0.08, respectively; p = 0.035). Additionally, waist:hip ratio, waist circumference, and 
resting HR differences were trending toward significance (p = 0.067, p = 0.082, and p = 
0.093, respectively), with all three measures lower in the responders than the non-
responders. There were no differences in compliance to curcumin pill consumption 
between the responders and the non-responders (95.33 ± 0.08% v. 95.08 ± 0.04%, p = 
0.950). 
The responders saw a significant decrease in cfPWV (6.81 ± 0.83 m/s to 5.92 ± 
0.36 m/s, p = 0.025, group by time interaction), and group comparisons between the 
responders and the non-responders to curcumin can be found in Table 4-3. There was a 
group by time interaction between the responders and non-responders (p = 0.025), and 
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the effect of time was significant in the responders (p = 0.048) but not in the non-
responders (p = 0.282). Additionally, in Figure 4-3, the cfPWV measures from 0 to 12 
weeks in the responders are depicted. Interestingly, the responders demonstrated 
increases in anti-inflammatory cytokine IL-13 (4.52 ± 4.67 to 4.83 ± 4.71) in conjunction 
with decreases in cfPWV (p = 0.052, group by time interaction). Table 4-4 shows a 
significant effect of time on responders (p = 0.018) but not non-responders (p = 0.198).  
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Table 4-2. Baseline characteristics of responders and non-responders to the 
curcumin intervention 
 Responders (n = 6) Non-responders (n = 5) p-value 
Age (years) 25.17 ± 4.17 26.80 ± 5.12 0.670 
Height (cm) 179.25 ± 7.38 177.08 ± 5.87 0.169 
Weight (kg) 102.72 ± 12.12 110.22 ± 20.08 0.592 
Body Mass Index (kg/m2) 31.87 ± 1.67 35.00 ± 4.88 0.162 
Hip circumference (cm) 111.89 ± 6.53 117.57 ± 10.07 0.261 
Waist circumference (cm) 103.63 ± 5.32 115.28 ± 15.21 0.082 
Body fat (%) 25.60 ± 3.41 29.16 ± 6.07 0.115 
Fat mass (kg) 26.52 ± 5.93 33.00 ± 12.94 0.273 
Fat-free mass (kg) 76.20 ± 7.07 77.22 ± 8.32 0.808 
Waist:hip ratio 0.93 ± 0.04 0.98 ± 0.05 0.067 
Waist:height ratio 0.58 ± 0.03 0.65 ± 0.08 0.035* 
Brachial SBP (mmHg) 121.00 ± 10.41 126.80 ± 4.60 0.308 
Brachial DBP (mmHg) 76.33 ± 8.14 78.00 ± 10.86 0.474 
Brachial PP (mmHg) 44.67 ± 11.57 48.80 ± 9.01 0.722 
Brachial MAP (mmHg) 91.22 ± 7.11 94.27 ± 8.23 0.325 
Central SBP (mmHg) 103.50 ± 6.72 108.20 ± 7.40 0.239 
Central DBP (mmHg) 76.83 ± 8.33 78.60 ± 10.64 0.447 
Central PP (mmHg) 26.67 ± 5.96 29.60 ± 6.73 0.723 
Central MAP (mmHg) 85.72 ± 7.31 88.47 ± 9.15 0.333 
Aortic AIx (%) -2.67 ± 12.53 1.80 ± 12.03 0.560 
Aortic AIx75 (%) -12.50 ± 14.52 -5.80 ± 12.81 0.384 
Resting HR (bpm) 56.00 ± 5.48 59.80 ± 8.04 0.093 
cfPWV (m/s) 6.81 ± 0.83 5.84 ± 0.41 0.045* 
Reactive Hyperemia Index 2.11 ± 0.55 1.94 ± 0.49 0.204 
IFN-γ (pg/mL) 3.00 ± 1.18 c 2.89 ± 0.76  0.670 
IL-2 (pg/mL) 0.22 ± 0.17 c 0.11 ± 0.05  0.189 
IL-4 (pg/mL) 0.08 ± 0.07 c 0.07 ± 0.02  0.570 
IL-6 (pg/mL) 0.60 ± 0.21 c 0.94 ± 0.35  0.317 
IL-8 (pg/mL) 3.69 ± 0.69 c 3.72 ± 0.83  0.571 
IL-10 (pg/mL) 0.31 ± 0.13 c 0.27 ± 0.09  0.428 
IL-12 p70 (pg/mL) 0.38 ± 0.31 c 0.26 ± 0.03  0.434 
IL-13 (pg/mL) 4.52 ± 4.68 c 3.31 ± 2.17  0.474 
TNF-α (pg/mL) 1.54 ± 0.18 c 1.97 ± 0.62  0.107 
cn = 5; *p < 0.05, between groups. Values are means ± SD. SBP = Systolic Blood 
Pressure; DBP = Diastolic Blood Pressure; PP = Pulse Pressure; MAP = Mean Arterial 
Pressure; HR = Heart Rate; cfPWV = carotid-femoral Pulse Wave Velocity; AIx = 
Augmentation Index; AIx75 = Augmentation Index Corrected for Heart Rate of 75; IFN = 
Interferon; IL = Interleukin; TNF = Tumor Necrosis Factor
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Figure 4-2. Baseline cfPWV of responders and non-responders to curcumin 
treatment 
 
*p < 0.05, between groups; Means ± SEM. cfPWV = carotid-femoral Pulse Wave 
Velocity
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Table 4-3. Changes in cfPWV throughout the intervention in curcumin responders and non-responders  
  Visit 1 Visit 2 Visit 3    Visit 4 
Responders (n = 6) 6.81 ± 0.83   6.27 ± 0.34*   5.86 ± 0.49ǂ* 5.92 ± 0.36ǂ* 
Non-responders (n = 5) 5.94 ± 0.41 6.59 ± 0.26 6.53 ± 0.43 6.75 ± 0.71 
*p < 0.05, group by time interaction; ǂp < 0.05, effect of time. Values are means ± SD.  
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Figure 4-3. Changes in cfPWV throughout the intervention in curcumin responders (n = 6)  
 
ǂp < 0.05, effect of time; Means ± SEM 
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Table 4-4. Changes in IL-13 pre and post intervention in curcumin responders and non-responders  
  Visit 1 Visit 4 
Responders (n = 5) 4.52 ± 4.67 4.83 ± 4.71ǂ 
Non-responders (n = 5) 3.31 ± 2.17 2.70 ± 2.07 
ǂp < 0.05, effect of time. Values are means ± SD. 
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Secondary Variables of Interest 
Augmentation Index 
 Baseline differences in AIx and AIx75 were not present between the curcumin and 
placebo groups, as can be seen in Table 4-1. Table 4-5 shows the change in AIx and 
AIx75 from the beginning to the end of the study. After 12 weeks of supplementation, the 
interaction of group and time was significant for AIx (p = 0.034), indicating that the 
placebo treatment was more favorable on AIx than the intervention. The decrease in AIx 
in the placebo group compared to the curcumin group throughout the duration of the 
study can be seen in Figure 4-4. Nonetheless, this decrease was not apparent after 
adjusting the AIx for a heart rate of 75 (AIx75). The lack of significant change between 
groups in AIx75 are depicted in Figure 4-5. 
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Table 4-5. Effects of treatment on augmentation index 
  Curcumin (n = 11) Placebo (n = 11)   
  Before After Before After p-value 
Aortic AIx (%) -0.64 ±  11.91 3.82 ± 9.61 7.55 ± 10.14 -0.36 ± 10.89 0.034* 
Aortic AIx75 (%) -9.45 ± 13.54 -4.18 ± 10.56 -5.00 ± 10.54 -6.00 ± 11.71 0.571 
*p < 0.05, group by time interaction. Values are means ± SD. AIx = Augmentation Index; AIx75 = Augmentation Index Corrected for 
Heart Rate 75 
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Figure 4-4. Changes in AIx in curcumin and placebo groups throughout the 
intervention
 
*p < 0.05, group by time interaction; Means ± SEM 
 
Figure 4-5. Changes in AIx75 in curcumin and placebo groups throughout the 
intervention 
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Reactive Hyperemia Index 
 There was no difference between the groups in baseline RHI measured via the 
Endo-PAT 2000, as shown in Table 4-1. Additionally, no group by time interaction 
occurred after the 12 week intervention (Table 4-6). RHI was unchanged throughout the 
study in both groups (Figure 4-6). 
Inflammatory cytokines 
 Baseline inflammatory cytokine measures are shown in Table 4-1. There were no 
differences at baseline between the curcumin and placebo groups, although pro-
inflammatory cytokine IL-2 and anti-inflammatory cytokine IL-13 were trending, 
demonstrating increased concentrations in the placebo group (p = 0.052 and p = 0.075, 
respectively). Changes in inflammatory cytokines throughout the study are shown in 
Table 4-6. There were no group by time interactions in the inflammatory markers after 12 
weeks of intervention. However, a trending increase in anti-inflammatory cytokine IL-10 
was found following 12 weeks of intervention with curcumin when compared to the 
placebo (p = 0.071). Figure 4-7 illustrates changes in IL-10 from the beginning to the end 
of the study in both groups.
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Table 4-6. Effects of treatment on endothelial function and inflammatory cytokines 
  Curcumin (n = 10) Placebo (n = 9)   
  Before After Before After p-value 
Reactive Hyperemia Index 2.02 ± 0.50 1.99 ± 0.72d 2.08 ± 0.53 d 1.98 ± 0.45 d  0.951 
IFN-γ (pg/mL) 2.94 ± 0.94  2.76 ± 0.69 4.51 ± 0.66  3.82 ± 1.89  0.416 
IL-1β (pg/mL) n.d. n.d. n.d.  n.d.   
IL-2 (pg/mL) 0.17 ± 0.13  0.17 ± 0.14 0.45 ± 0.42  0.44 ± 048  0.772 
IL-4 (pg/mL) 0.07 ± 0.05  0.07 ± 0.06 0.12 ± 0.10  0.11 ± 0.13 0.928 
IL-6 (pg/mL) 0.77 ± 0.33  0.70 ± 0.38 0.62 ± 0.27  0.80 ± 0.62  0.215 
IL-8 (pg/mL) 3.71 ± 0.72  3.56 ± 1.17 3.48 ± 0.72  3.51 ± 1.19  0.730 
IL-10 (pg/mL) 0.29 ± 0.11  0.34 ± 0.13 0.45 ± 0.32  0.41 ± 0.31  0.071 
IL-12 p70 (pg/mL) 0.32 ± 0.22  0.29 ± 0.23 0.50 ± 0.38  0.44 ± 0.48  0.596 
IL-13 (pg/mL) 3.92 ± 3.50  3.77 ± 3.61 9.00 ± 3.37  9.53 ± 9.02  0.431 
TNF-α (pg/mL) 1.76 ± 0.49 1.89 ± 0.63 1.71 ± 0.45  1.72 ± 0.51  0.375 
dn = 11; n.d. = not detectable; *p < 0.05, group by time interaction. Values are means ± SD. IFN= Interferon; IL = Interleukin; TNF = 
Tumor Necrosis Factor; n/d = not detectable
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Figure 4-6. Changes in RHI in curcumin and placebo groups pre and post 
intervention 
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Figure 4-7. Changes in anti-inflammatory cytokine IL-10 in curcumin and placebo 
groups pre and post intervention 
 
p value is group by time interaction. Means ± SEM 
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Blood Pressure and Heart Rate Measures 
There were no baseline differences in brachial SBP, DBP, PP, MAP; central SBP, 
DBP, PP, MAP; or resting radial HR between groups. After 12 weeks of 
supplementation, a significant decrease in the curcumin group in comparison to the 
placebo group was found in brachial PP (p = 0.038, group by time interaction) but not 
central PP (p = 0.256, group by time interaction). Table 4-7 shows changes in BP and HR 
measures from the beginning to the end of the study. The significant decrease in brachial 
PP in the curcumin group can be seen in Figure 4-8, while the lack of significant change 
in central PP can be seen in Figure 4-9. No group by time interactions were seen in radial 
HR; brachial SBP, DBP, or MAP; or central SBP, DBP, or MAP following 12 weeks of 
supplementation with curcumin or placebo. However, there was a significant effect of 
time on Brachial SBP (p = 0.030), indicating improvements in both groups. 
 
  
 
88 
Table 4-7. Effects of treatment on BP and HR measures 
  Curcumin (n = 11) Placebo (n = 11)   
  Before After Before After p-value 
Brachial SBP (mmHg) 123.64 ± 8.48 118.73 ± 8.64 124.91 ± 8.96 122.91 ± 8.07 0.731ǂ 
Brachial DBP (mmHg) 77.09 ± 9.01 78.73 ± 7.60 81.82 ± 5.40 79.64 ± 5.64 0.350 
Brachial PP (mmHg) 46.55 ± 10.20 40.00 ± 9.42 43.09 ± 6.41 43.27 ± 6.34 0.038* 
Brachial MAP (mmHg) 92.61 ± 7.41 92.06 ± 6.61  96.18 ± 6.09 94.06 ± 5.83 0.538 
Central SBP (mmHg) 105.64 ± 7.10 104.73 ± 7.76 109.18 ± 6.10 106.55 ± 6.04 0.620 
Central DBP (mmHg) 77.64 ± 8.99 79.36 ± 8.20 82.18 ± 5.62 79.91 ± 5.47 0.383 
Central PP (mmHg) 28.00 ± 6.18 25.36 ± 6.22 27.00 ± 4.86 26.64 ± 3.29 0.256 
Central MAP (mmHg) 86.97 ± 7.89 87.82 ± 7.50 91.18 ± 5.31 88.79 ± 7.50 0.423 
Resting HR (bpm) 57.90 ± 6.79 58.82 ± 10.44 56.64 ± 4.82 62.64 ± 8.19 0.163 
*p < 0.05, group by time interaction. ǂp < 0.05, main effect of time. Values are means ± SD. SBP = Systolic Blood Pressure; DBP = 
Diastolic Blood Pressure; PP = Pulse Pressure; MAP = Mean Arterial Pressure; HR = Heart Rate 
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Figure 4-8. Changes in Brachial PP in curcumin and placebo groups throughout the 
intervention 
 
*p < 0.05, group by time interaction; Means ± SEM 
 
Figure 4-9. Changes in Central PP in curcumin and placebo groups throughout the 
intervention 
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Other Physiological Measures 
Body Composition 
 At baseline, there were no differences in body composition measures (Table 4-1). 
There were no significant changes in measures of body composition throughout the 12 
week intervention between groups (Table 4-8). 
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Table 4-8. Effects of treatment on body composition 
  Curcumin (n = 11) Placebo (n = 11)   
  Before After Before After p-value 
Body fat (%) 27.22 ± 4.90 28.52 ± 4.42 27.18 ± 5.46 27.79 ± 5.62 0.371 
Body Mass Index (kg/m2) 33.29 ± 3.69 33.99 ± 3.42 33.18 ± 3.38 33.57 ± 3.82 0.145 
Weight (kg) 106.13 ± 15.81 108.59 ± 15.36 102.34 ± 11.60 104.28 ± 11.60 0.117 
Fat mass (kg) 29.46 ± 9.80 31.43 ± 9.24 28.32 ± 9.22 29.55 ± 9.65 0.322 
Fat-free mass (kg) 76.66 ± 7.28 77.17 ± 7.62 73.97 ± 4.07 74.73 ± 3.17 0.207 
Waist circumference (cm) 108.93 ± 11.99 109.32 ± 11.98 106.27 ± 10.37 106.27 ± 12.29 0.578 
Hip circumference (cm) 114.47 ± 8.41 115.36 ± 6.97 112.80 ± 5.87 112.92 ± 5.43  0.104 
Waist:hip Ratio 0.95 ± 0.05 0.95 ± 0.06 0.94 ± 0.06 0.94 ± 0.07 0.295 
Waist:height Ratio 0.61 ± 0.07 0.61 ± 0.07 0.61 ± 0.06 0.60 ± 0.07 0.711 
*p < 0.05, group by time interaction. Values are means ± SD.  
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Dietary History Questionnaire 
 At baseline, the total HEI scores were not significantly different between the 
curcumin and placebo groups (p = 0.464). Only refined grain scores were higher in the 
placebo group compared to the curcumin group (p = 0.049). No other baseline differences 
were seen in HEI score components. Baseline scores and differences between groups can 
be seen in Table 4-9.  
Table 4-10 contains the differences in dietary habits from the beginning to the end 
of the study in both groups. There was not a significant group by time interaction of the 
overall HEI scores. However, pre and post scores indicate differences in the HEI scores 
for greens and beans between the groups (p = 0.005, group by time interaction), showing 
a significantly higher consumption of greens and beans in the placebo group than in the 
intervention group at the conclusion of the study. There were no differences in other HEI 
dietary components revealing a group by time interaction. 
 
  
 
93 
Table 4-9. Baseline differences in dietary intake for curcumin and placebo groups 
  Curcumin (n = 11) Placebo (n = 11) p-value 
Total HEI Score 62.78 ± 12.79 67.32 ± 13.81 0.464 
Total Vegetables (HEI Score) 3.84 ± 1.19 4.03 ± 1.20 0.705 
Greens and Beans (HEI Score) 3.48 ± 1.81 3.92 ± 1.43 0.493 
Total Fruit (HEI Score) 3.14 ± 1.65 2.71 ± 1.71 0.587 
Whole Fruit (HEI Score) 3.91 ± 1.75 3.25 ± 1.85 0.434 
Refined Grains (HEI Score) 7.42 ± 1.78 8.68 ± 1.93 0.049* 
Whole Grains (HEI Score) 1.76 ± 0.83 1.67 ± 1.23 0.879 
Dairy (HEI Score) 6.36 ± 2.84 7.56 ± 1.98 0.375 
Total Protein Foods (HEI Score) 4.73 ± 0.59 4.79 ± 0.35 0.824 
Seafood and Plant Proteins (HEI Score) 3.47 ± 1.69 4.09 ± 1.42 0.364 
Fatty Acids (HEI Score) 5.17 ± 3.19 5.89 ± 3.80 0.658 
Sodium (HEI Score) 4.06 ± 2.09 4.79 ± 2.76 0.522 
Empty Calories (HEI Score) 15.4 ± 3.88 15.94 ± 6.24 0.841 
*p < 0.05, between groups. Values are means ± SD. HEI = Healthy Eating Index 
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Table 4-10. Changes in dietary intake from baseline to the end of the study 
  Curcumin (n = 11) Placebo (n = 11)   
  Before After Before After p-value 
Total HEI Score 62.78 ± 12.79 60.71 ± 13.23 67.32 ± 13.81 64.74 ± 12.74 0.883 
Total Vegetables (HEI Score) 3.84 ± 1.19 3.67 ± 1.29 4.03 ± 1.20 4.34 ± 0.83 0.235 
Greens and Beans (HEI Score) 3.48 ± 1.81 2.87 ± 2.24 3.92 ± 1.43 4.97 ± 0.06 0.005* 
Total Fruit (HEI Score) 3.14 ± 1.65 2.57 ± 1.53 2.71 ± 1.71 2.51 ± 1.95 0.496 
Whole Fruit (HEI Score) 3.91 ± 1.75 3.44 ± 1.65 3.25 ± 1.85 3.23 ± 2.10 0.367 
Refined Grains (HEI Score) 7.42 ± 1.78 8.47 ± 2.08 8.68 ± 1.93 8.56 ± 1.94 0.122 
Whole Grains (HEI Score) 1.76 ± 0.83 2.04 ± 0.68 1.67 ± 1.23 1.83 ± 1.52 0.787 
Dairy (HEI Score) 6.36 ± 2.84 4.92 ± 3.30 7.56 ± 1.98 6.08 ± 2.45 0.982 
Total Protein Foods (HEI Score) 4.73 ± 0.59 4.47 ± 0.89 4.79 ± 0.35 4.81 ± 0.64 0.290 
Seafood and Plant Proteins (HEI Score) 3.47 ± 1.69 4.01 ± 1.68 4.09 ± 1.42 4.02 ± 1.36 0.202 
Fatty Acids (HEI Score) 5.17 ± 3.19 5.55 ± 3.51 5.89 ± 3.80 4.95 ± 2.87 0.292 
Sodium (HEI Score) 4.06 ± 2.09 4.90 ± 3.05 4.79 ± 2.76 4.60 ± 2.91 0.323 
Empty Calories (HEI Score) 15.4 ± 3.88 13.80 ± 6.06 15.94 ± 6.24 14.81 ± 6.09 0.833 
*p < 0.05, group by time interaction. Values are means ± SD. HEI = Healthy Eating Index 
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CHAPTER V 
DISCUSSION AND CONCLUSION 
 The purpose of this study was to determine if 12 weeks of supplementation with 
curcumin (1.0 g/day) could improve arterial stiffness, endothelial dysfunction, and 
inflammation in young obese men. This study was the first to assess curcumin as a novel 
intervention for vascular health in young, obese men.  
 The major finding of this study was that curcumin caused a reduction in cfPWV 
in young obese men with baseline elevated cfPWV. Furthermore, curcumin caused 
significant reductions in brachial PP, a surrogate marker of arterial stiffness. The current 
study may provide support for improvements in vascular health with curcumin 
supplementation in young obese men, especially when they present with increased 
cfPWV.  
Arterial Stiffness as Measured by cfPWV 
Over the 12 week study, some individuals responded to the curcumin treatment 
with reductions in cfPWV while others did not. The curcumin group did not see 
significant changes in cfPWV compared to the placebo group. The overall lack of 
reduction in cfPWV in the curcumin group when compared to the placebo group is 
consistent with the previous findings in a pilot study looking at the potential role of 
curcumin on the vascular health of PM women (322). However, findings in another study 
from the same lab did show significant increases in arterial compliance, the reciprocal of 
arterial stiffness (9). Arterial compliance was not measured in the current study.  
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Exploratory statistics were employed to see if any inferences might be made about 
why some individuals responded to the curcumin treatment and others did not. It was 
shown that those individuals who responded to the curcumin had a higher baseline 
cfPWV than the non-responders (mean: 6.81 m/s v. 5.84 m/s, p = 0.045), showing nearly 
a 1.0 m/s difference in cfPWV measures at baseline. Interestingly, the responders had 
cfPWV values that were above reference values for their age group, while non-
responders were below reference values. Established reference values show that 
individuals less than 30 years of age with normal blood pressure readings and no other 
cardiovascular risk factors had a mean PWV of 6.2 m/s, and individuals 30-40 years of 
age had a mean PWV of 6.5 m/s (271). This might suggest that curcumin could 
potentially benefit arterial stiffness in individuals who have higher than average cfPWV 
measures for their age. In addition to the higher cfPWV measures in the responders, 
waist:height ratios were significantly lower in the responders (p = 0.035), while waist:hip 
ratios and waist circumference measures were trending toward significance (p = 0.067 
and p = 0.035, respectively). This could suggest that distribution of body fat may be 
playing a role in the responsiveness to the treatment, with the unexpected supposition that 
those individuals with a higher distribution of fat in the waist might not respond to the 
curcumin treatment. There is currently no evidence to suggest that distribution of body fat 
might determine responsiveness to curcumin, but abdominal adiposity is associated with 
low-grade chronic inflammation (105, 116, 168, 383). In the current work, waist 
circumference is positively associated with inflammation, as determined by pro-
inflammatory markers TNF-α (p = 0.019) and IL-8 (p = 0.031). The known anti-
inflammatory properties of curcumin (4, 11, 32, 62, 161) would indicate the potential for 
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curcumin to have a more pronounced impact on individuals with increased waist 
circumference measures. Therefore, it is unlikely that responsiveness is determined by 
lower waist circumference, waist:hip ratio, and waist:height ratio Additionally, the 
resting HR differences at baseline were trending toward significance (p = 0.093), with the 
responders presenting with lower baseline HR measures. While the possibility cannot be 
excluded that individuals with higher HR measure might not respond to curcumin, there 
is  little evidence to support this theory, and it is unlikely since both groups had mean HR 
values that were low enough to be considered bradycardic. However, the trending 
difference in baseline HR between responders and non-responders could suggest that the 
individuals identified as responders had increased cardiovascular fitness at baseline, as 
higher activity levels are associated with lower HRs (298). In contrast, this is not likely 
because the responders had cfPWV measures that were nearly 1.0 m/s higher than the 
non-responders, and physical activity is a strong predictor of cfPWV (20, 245, 329) . 
Additionally, while there is little evidence to support that individuals who are more active 
will respond more favorably to curcumin compared to less active individuals, 
interventions that incorporate both curcumin and exercise have shown an interaction 
effect between exercise and curcumin on arterial compliance when initiated together (9). 
Nevertheless, intervening with exercise and curcumin concomitantly did not have an 
effect on cfPWV (322). Thus, while the possibility remains that lower baseline HR 
measures could be indicative of increased physical activity levels, cfPWV measures do 
not suggest that the responders had higher physical activity levels, and previous work 
does not indicate that increased physical activity levels will increase responsiveness to 
curcumin. Therefore, the most likely explanation for the responsiveness of arterial 
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stiffness to curcumin is that the individuals that did respond had higher cfPWV measures 
at baseline. 
Due to the benefits of curcumin on arterial stiffness for a subset of individuals 
who had higher cfPWV values at baseline, insight was sought into the mechanistic role 
determining responsiveness. Of note, the decrease in cfPWV values corresponded with an 
increase in anti-inflammatory IL-13 in the responders (effect of time in responders, p = 
0.018) when compared to the non-responders (p = 0.052, group by time interaction). The 
effects of curcumin on inflammatory cytokines are believed to occur through the ability 
of curcumin to inhibit NFĸB signaling, and therefore, modify the downstream 
inflammatory pathways that it regulates (333). Curcumin inhibits the activation of NFĸB 
(126, 303) and can affect downstream inflammatory cytokines (122, 126). A possible 
mechanism for reductions in arterial stiffness in the responders could be the 
corresponding increase in cytokine IL-13. To our knowledge, other arterial stiffness 
studies have not shown reductions in cfPWV that are associated with increases in IL-13. 
However, IL-13 has been shown to have a protective role in a murine model against 
atherosclerosis (55), a separate but related arterial pathology. Anti-inflammatory cytokine 
IL-13 modulated atherosclerotic lesions through structural changes in collagen fibers. 
Arterial stiffness is also modulated by structural changes in collagen fibers (58), and 
collagen cross-linking breakers have resulted in significant reductions in cfPWV through 
an effect on AGEs in experimental animals (25, 69, 344, 376) and humans (163). 
Furthermore, a study looking at the effect of curcumin on the large elastic artery stiffness 
in aging mice showed amelioration of collagen content and AGEs corresponding with 
reductions in PWV (113). Other possible explanations for reductions in cfPWV should 
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also be considered. In mice, cfPWV reductions due to curcumin were also associated 
with MnSOD expression attenuation and nitrotyrosine reduction, leading to amelioration 
of oxidative stress (113). Additionally, TEMPOL, a mimetic of antioxidant SOD, has 
ameliorated arterial stiffness by normalizing collagen and oxidative stress (111). The 
current study did not look at changes in oxidative stress associated with reductions in 
cfPWV, so this could be a possible mechanism by which curcumin reduces arterial 
stiffness in the responders. 
 Vascular health of young, obese individuals is a relevant clinical concern. Most 
studies looking at the predictive power of cfPWV in determining cardiovascular events 
have occurred in middle-aged and older adults; studies in younger individuals are lacking 
but could provide pertinent understanding in early adaptations of arterial structure and 
CVD risk progression (238). Furthermore, the potential to identify and alter vascular 
parameters at a younger age could lead to an ability to favorably reduce or prevent the 
development of CVD, affecting quality of life in these individuals for more substantial 
time periods.  
Other studies have looked at associations of various parameters with cfPWV to 
better understand the factors that might predict arterial stiffness. In previous studies, 
obesity has been shown to lead to stiffer arteries, when individuals are compared to age-
matched counterparts (79) at all ages from adolescence to old age (384) independent of 
BP, ethnicity, and age (280). Interestingly, in the current study, the cfPWV measurements 
were not elevated from normative data of age-matched counterparts when considering 
group mean. As a whole, the values for cfPWV in this study were much healthier than 
anticipated for an obese cohort, showing obese men presenting with a mean cfPWV of 
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6.29 ± 0.88 m/s at baseline. In this study, it was found that BMI was not a significant 
predictor of cfPWV (p = 0.376). Many other studies have shown that obesity based on 
BMI does not necessarily lead to higher cfPWV measures (57, 78, 279, 285, 386).  
While BMI is not always the best indicator of health risk due to obesity, 
especially in individuals with larger than normal muscle mass (134), all subjects in this 
study were also considered to have elevated body fat percentages. The American College 
of Sports Medicine states that men aged 20-39 are considered to have a “poor” body fat 
percentage at 19.7-24.8% body fat or “very poor” body fat percentage at 24.9-33.4% 
body fat (15). The average body fat percentage of the men in this study was 27.2 ± 5.1% 
at baseline. Of the 22 subjects enrolled in this study, eight men (36.3%) had “poor” body 
fat percentages and 14 men (63.6%) had “very poor” body fat percentages. Although 
subjects were randomized based on BMI, body fat percentage comparisons between the 
groups were nearly identical (27.22 ± 4.90% v. 27.18 ± 5.46%, p = 0.972). Some studies 
suggest that, rather than BMI, we should determine obesity by parameters such as body 
fat percentage (2, 282, 381) or central adiposity measures (280) in order to identify 
individuals who would present with stiffer arteries. However, in this study, increased 
body fat percentage was not predictive of cfPWV (p = 0.550). A study in middle-aged 
individuals also indicated that body fat percentage was not a significant predictor of 
cfPWV (318).  
It is believed that central adiposity may be associated with stiffer arteries due to 
increased levels of low-grade inflammation (281). In one study, when other obesity-
related measures were not positively associated with cfPWV, waist circumference was 
clearly associated with cfPWV (72). In the present study, waist circumference was not 
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significantly associated with cfPWV (p = 0.540); this same finding was reported in a 
study of the general population (79). Although obesity is known to be a pro-inflammatory 
state (105, 383), it is believed that visceral fat depots influence inflammatory markers 
more than BMI or body fat percentage (117). Studies have shown that waist 
circumference is associated with pro-inflammatory blood markers, such as CRP, IL-6, IL-
8, and TNF-α (105, 168, 383). The current study found that waist circumference was 
predictive of both TNF-α and IL-8 but no other pro-inflammatory markers (p = 0.031 and 
p = 0.019, respectively; univariate regression models can be seen in Table A-1).  
Other anthropometric measures were also considered. Waist:hip circumference 
was trending toward significance as a predictor of cfPWV (p = 0.058) in the obese men in 
the current study. It is not surprising that waist:hip circumference is nearly predictive of 
cfPWV, as importance in predicting cfPWV based on waist:hip ratio has been reported 
elsewhere in 20-40 year old individuals and 41-77 year old individuals (368). Another 
anthropometric measure taken into consideration was waist:height ratio, an index of 
abdominal adiposity that has proven useful in determining cardiometabolic risk (284). 
One study reported that the waist:height ratio has the strongest association with aortic 
stiffness and that it may be the preeminent measure of excess adiposity determining 
cfPWV in the general population (375). The authors suggest that waist:height ratio may 
provide a better prediction of aortic stiffness than waist circumference, as waist 
circumference is a proxy measure of abdominal adiposity that does not distinguish 
between two individuals with the same waist circumference yet dramatically different 
heights; therefore, waist circumference alone is unable to account for increased 
abdominal fat percentage with differing heights (375). In the current study, that was not 
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found to be true, as the waist:height ratio was not associated with cfPWV (p = 0.472). 
Moreover, body weight and hip circumference have shown strong correlations with 
increased PWV elsewhere (368). In the current study, neither overall body weight nor hip 
circumference were good predictors of cfPWV (p = 0.612 and p = 0.506). Other studies 
have shown a lack of association between cfPWV and hip circumference or overall body 
weight (34, 72). Thus, obesity-associated measures did not predict higher cfPWV 
measures in the current study, which is consistent with some previous studies but not 
others. 
There seems to be a lack of consensus in the literature about measures of obesity 
and their prediction of cfPWV. This could be due to differences in the population of 
interest within the studies or it could be due to the fact that other unfavorable conditions 
often present with obesity, leading to confounders such as metabolic syndrome, 
hypertension, and type 2 diabetes (34). Others have reported that measures of obesity are 
independently associated with higher values of cfPWV in women but not men, so sex 
could play a potential role in the discord that exists in the literature (242). Another 
possible explanation could be the age of obesity onset (1, 73, 104). Stiffer arteries have 
been associated with higher blood pressure and central adiposity measures in adolescents, 
leading to steeper increases in arterial stiffness in a 20 year follow-up period (104). Also, 
childhood obesity has been suggested to have a significant adverse effect on PWV in 
adolescents (73). The total number of risk factors in childhood and adulthood has been 
directly associated with PWV in adulthood, indicating that each of the following are 
independent predictors of PWV in adulthood: age, childhood SBP, childhood blood 
glucose, adulthood SBP, adulthood blood insulin, and adulthood triglycerides (1). 
 
 103 
 
Furthermore, this study also indicated that reductions in the total number of risk factors 
from childhood to adulthood were associated with lower PWV measures in adulthood. In 
the current study, age of obesity onset, and thus the duration of obesity, was not 
determined, but it may have given insight into why cfPWV values in this obese 
population were not significantly higher that age-matched norms. Another important 
consideration could be that the men in this study were considered “fit but fat” (94). 
Individuals who are defined as “fit but fat” are believed to exhibit increased 
cardiovascular fitness that attenuates obesity-associated cardiovascular risks. It is 
estimated that 9% of adults fall into this category (94). Measurements to define 
cardiovascular fitness were not considered for this study; thus, it cannot be excluded that 
cardiovascular fitness levels might be responsible for the lack of association between 
obesity and arterial stiffness. Based on the results of this study, young obese men do not 
necessarily have stiffer arteries as a result of obesity. 
For the current study, associations with cfPWV through univariate regression can 
be found in Table A-2 and through forward selection multiple regression in Table A-3. 
The only predictor of cfPWV that was found in this study from a simple regression model 
was pro-inflammatory cytokine IL-12 p70 (R2 = 0.258, p = 0.031). This is consistent with 
previous findings in healthy individuals (382). In addition to IL-12 p70, there were a few 
variables that were trending toward significance in their ability to predict cfPWV: 
waist:hip ratio (R2 = 0.177, p = 0.058), brachial SBP (R2 = 0.140, p = 0.094), brachial 
MAP (R2 = 0.175 , p = 0.059), central DBP (R2 = 0.148 , p = 0.085), central MAP (R2 = 
0.138 , p = 0.097), consumption of whole grains (R2 = 0.182 , p = 0.054), and 
consumption of refined grains (R2 = 0.148 , p = 0.085). Of note, age, the most 
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predominating independent predictor of cfPWV (180), was not a significant predictor of 
cfPWV in this sample (p = 0.268). A possible explanation for this is that, in a young, 
relatively homogenous group of young men, age confers no additional predictive value 
for cfPWV. The correlation of waist:hip ratio with cfPWV was discussed in detail above. 
Brachial SBP was the only predictor that prevailed in a forward selection model of 
multiple regression. Brachial SBP is a well-known predictor of cfPWV (1, 30, 143). 
Other studies have shown the association of brachial MAP (12, 48, 76, 217, 222), central 
DBP (262), and central MAP (199) with arterial stiffness. This is the first study to note a 
trending association between grain consumption (both whole and refined grains) and 
cfPWV. Whole grain consumption was negatively associated with cfPWV, whereas 
refined grain consumption was positively associated with cfPWV. Lower lifetime 
consumption of whole grains has been associated with stiffer carotid arteries, reportedly 
due to the impact of fiber content (348). Further explanations to clarify the diverging 
impact of whole and refined grains on these obese men could be vitamin and mineral 
content (specifically antioxidant content), resistant starch, oligosaccharides, phenolic 
compounds, and phytoestrogens (308). Further studies will need to be conducted to see if 
whole and refined grain consumption predicts arterial stiffness.  
Augmentation Index 
There was a significant group by time interaction for AIx. Interestingly, this 
interaction suggested potential benefit of the placebo rather than the intervention. 
However, when the augmentation index was corrected for a heart rate of 75 (AIx75), this 
interaction did not persist. AIx75 is considered a more acceptable measure of 
augmentation index, as it takes into account HR, and AIx is highly influenced by HR 
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(372). Therefore, since AIx corrected for HR (AIx75) is considered a more appropriate 
measure for determining arterial stiffness, fluctuations in HR might be responsible for the 
significant group by time interaction between the intervention and placebo groups (313, 
372).  
The limitations of AIx as a measure of arterial stiffness might give further 
elucidation as to why the placebo group saw improved augmentation indices when 
compared to the placebo. While the AIx has been reported to predict cardiovascular 
events and mortality (355), cfPWV has prevailed as a stronger predictor (216). This is 
due, in part, to the assumptions that underlie the general transfer function that is used to 
calculate the AIx (186). Not only has it been shown to produce a range of error (232), but 
the validation of this transfer function has been the object of criticism (63, 144, 186, 210, 
257). As the assumptions underlying the general transfer function have proven 
problematic in some instances (210), it may follow that the assumptions made are not 
appropriate for a young, obese cohort of men. Furthermore, the assumed reflection site of 
the incident wave may not be precise, causing inaccuracy in the measurement (186). 
Thus, the AIx may not serve as the best determinant of arterial stiffness in young obese 
men. 
Another possible explanation for the decrease in AIx in the placebo group could 
be the increased consumption of greens and beans. While all subjects were instructed to 
maintain current dietary habits throughout the study, a change in the greens and beans 
HEI score in the placebo group indicates that subjects may have incompletely adhered to 
these guidelines. The effect of diet on arterial stiffness has been elucidated previously 
(29, 53, 132, 197, 253, 255, 358), but previous studies have not considered the specific 
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role of greens and beans in altering arterial stiffness. (37). Dietary fiber, which tends to 
be high in these foods, has been reported to reduce the stiffness of the arteries (348). In 
one study reporting the effects of lifetime dietary intake on stiffness of the carotid artery, 
fiber intake was negatively associated with arterial stiffness (348). Dietary fiber can 
affect cardiovascular disease risk by lowering blood cholesterol concentrations and 
normalizing glucose and insulin (307), but whether these mechanisms are what directly 
affects the carotid stiffness associated with lower lifetime fiber intake is still not fully 
understood (348). Additionally, the dark green vegetables associated with the “greens and 
beans” category of the DHQ (86) are often high in dietary nitrates (145). Nitrates from 
green vegetables have been previously reported to affect arterial stiffness measured by 
AIx (160, 268). Nitrates present in vegetables will be reduced to nitrite and converted to 
NO, which will increase NO bioavailability in the vasculature (268). Importantly, 
increased NO bioavailability has been shown to reduce arterial stiffness (37, 112, 302). 
The potential role of greens and beans in the reduction of AIx in the placebo group 
cannot be eliminated. However, since cfPWV, a more robust measure of arterial stiffness, 
was not affected as a result of this dietary change, it is unlikely that the increased 
consumption of greens and beans explains the change in AIx.  
It must be noted that the placebo was composed of fenugreek. Fenugreek could 
potentially affect arterial stiffness, but previous literature has not explored this 
possibility. Fenugreek, the naturally occurring medicinal plant, is composed of 50% fiber 
(31), and fiber can attenuate arterial stiffness (348). Additionally, fenugreek has also been 
shown to favorably influence glucose (129, 291), cholesterol (293), and triglyceride 
concentrations (294, 295). However, the curcumin intervention also contained the same 
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amount of fenugreek to enhance the bioavailability of curcumin, so similar changes 
would have been expected in the intervention group as well. Therefore, while this 
possibility cannot be eliminated that fenugreek alone is more beneficial to arterial health 
(as determined by AIx) than curcumin and fenugreek combined, it is not probable.  
Reactive Hyperemia Index 
Endothelial function was not impacted by curcumin supplementation in the 
current study. This was unexpected given previous findings in PM women showing 
improvements in endothelial function after eight weeks of supplementation with 
curcumin (8). A likely explanation might be that the previous study in PM women used a 
different method for monitoring endothelial function than the current study. The previous 
study used a technique for measuring FMD with ultrasound, the gold standard non-
invasive technique for measuring endothelial function (95). It should be noted that PAT is 
not the gold-standard method of determining endothelial function, and some studies have 
shown that FMD and PAT are not associated (85, 133, 187, 286, 327) while others have 
shown association between the two methods (83, 139, 178, 250, 369). In an obese cohort 
specifically, FMD and PAT measures were not correlated (85). It is believed that these 
disparities that exist might be due in part to the population that is being tested (13, 187) 
or due to the fact that PAT might not be strictly measuring NO-mediated dilation (13). 
Several studies suggest that PAT is measuring more complex mechanisms than strict NO-
dependent vasodilation (13, 85, 95). Furthermore, it has been suggested that PAT is not a 
sensitive measure of endothelial function based on its lack of ability to distinguish 
between healthy individuals and those with known peripheral arterial disease, whereas 
FMD could distinguish between individuals with peripheral arterial disease (13). 
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Therefore, differences between the current study and the study in PM women are likely 
due to different techniques employed for measuring endothelial function. 
The manufacturer’s guidelines for the Endo-PAT 2000 designate that the 
threshold for a good EndoPAT result is 1.67 (150). At baseline, the mean RHI was 
reported to be 2.05 ± 0.50 in the present cohort of obese men. Only four men had baseline 
scores that fell below the threshold value of 1.67. Differences in results between the 
current study and the previous study in PM women could also be due to reduced 
endothelial function in these women at baseline (8). It has been reported in other studies 
that compromised endothelial function due to obesity may be more specific to the female 
sex (320) or may occur in obese male populations when both increased BMI and older 
age are present (23, 102, 127). Therefore, when values are considered normal at baseline, 
there may not be a great probability of seeing improvement.  
Furthermore, it has been postulated that curcumin exerts its effects on endothelial 
function through suppression of inflammation and oxidative stress by down-regulating 
TNF-α (137). Since TNF-α remained unchanged in the current study, this could be a 
possible explanation for why no improvements were seen in endothelial function. The 
study in PM did not assess plasma TNF-α levels to confirm similar mechanisms 
occurring in conjunction with improvements in endothelial function (8).  
Inflammatory Cytokines 
 Curcumin is a well-documented anti-inflammatory agent, and its anti-
inflammatory properties have been the focus of several reviews (4, 32, 62, 161, 297). The 
number of clinical trials focusing on curcumin is growing, and previous clinical trials 
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show promise for curcumin’s therapeutic potential against many diseases (130). Very few 
clinical trials have looked at the impact of curcumin on the cardiovascular system, but the 
few that have, have not looked at the impact on inflammatory cytokines (14, 311). 
Arterial stiffness is associated with inflammation (204, 357), and inflammation affects 
structural changes within the arteries (159). Since arterial stiffness is associated with pro-
inflammatory cytokines (188), the ability to impact inflammation in cases of arterial 
stiffness could be of great clinical importance (204, 357).  
 Various clinical trials have shown that inflammatory cytokines are impacted by 
curcumin treatment in colorectal cancer (137), pancreatic cancer (82), head and neck 
cancer (171), irritable bowel disease (97), osteoarthritis (36), type 2 diabetes (343), and 
diabetic nephropathy (166). The application of curcumin’s anti-inflammatory properties 
in various diseases might not be transferable from one disease state to the next. In the 
current study, involving obese but otherwise healthy young men, no significant plasma 
cytokine level differences were found, but anti-inflammatory cytokine IL-10 was 
trending toward an increase in the curcumin compared to placebo group. Increased IL-10 
levels following curcumin treatment have been reported elsewhere (82, 97, 100, 385). A 
previous study has suggested curcumin may be able to increase IL-10 expression through 
inhibition of acetylation, but the specific mechanisms are still unknown (97). Increased 
plasma IL-10 levels are of importance because of the anti-inflammatory nature of IL-10 
(221), whereby it can inhibit the production of pro-inflammatory cytokines (107). 
 No other differences in inflammatory markers were noticed in this study in the 
curcumin group when compared to the placebo group. Other studies have found that IL-
1β (36, 97), IL-6 (36, 82, 343), IL-8 (82, 166, 171), IL-10 (82, 97), and TNF-α (137, 343) 
 
 110 
 
were significantly affected after curcumin treatment. Inconsistencies between the 
previous clinical trials and this one include differences in age, disease state, and sex of 
the subjects as well as different intervention treatments; curcumin has been studied alone 
and in combination with quercetin, gemcitabine, piperine, docetaxel, soy isoflavones, 
bioperine, sulfasalazine, mesalamine, prednisone, lactoferrin, N-acetylcysteine, and 
pantoprazole (130). The current combination of fenugreek with curcumin has not been 
tested in other trials, and young obese men have not been the focus of the other studies 
mentioned.  
Blood Pressure and Heart Rate Measures 
 Curcumin supplementation significantly reduced brachial PP when compared to 
the placebo (46.55 ± 10.20 mmHg to 40.00 ± 9.42 mmHg, p = 0.038, group by time 
interaction). The current study and the studies in PM women seem to suggest that 
changes in BP occur more readily with curcumin than changes in cfPWV (9, 322). In the 
current study, there was a significant time effect on SBP (p = 0.030), but the curcumin 
group did not show reductions in SBP that were significantly different than the placebo 
group. In PM women, brachial SBP was reduced, but brachial PP did not change 
significantly (9). This could likely be due to the corresponding changes that occurred in 
DBP in PM women, which resulted in similar PP measures after the eight week 
intervention period. Curcumin’s ability to impact brachial PP is, therefore, unique to the 
current study. 
Brachial PP is accepted as a surrogate marker of arterial stiffness (185). Notably, 
brachial PP was reduced in the curcumin group, while cfPWV was not. Although brachial 
PP has been shown to correlate well with cfPWV in the general population, dissociations 
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have been known to occur in younger individuals (218, 347). This finding suggests that 
functional rather than structural differences are causing the overall reduction in brachial 
PP seen in the curcumin group. If structural differences in the artery were present 
amongst the individuals in the curcumin group, one would expect to see significant 
reductions in cfPWV in the group as a whole. Reductions in cfPWV in the six responders 
in the curcumin group could possibly be a result of structural changes in the arteries, 
presumably through anti-inflammatory IL-13. However, other mechanisms seem to be 
responsible for the overall reduction in brachial PP that is seen in the group as a whole, 
including the individuals who were non-responders based on cfPWV. A few explanations 
for this functional, rather than structural, change could be possible.  
The role of vascular smooth muscle cells might be the primary action by which 
reductions in brachial PP were seen. Vascular smooth muscle cells, which produce 
different levels of active tone, can contribute to the functional ability of the arteries to 
vasodilate or vasoconstrict (120). With aging, the structural components of the arteries 
are known to work in conjunction with the vasoactive function of vascular smooth 
muscle cells, although the structural components have been shown to contribute to 
arterial stiffness more with age (49, 120). In this young group of men, curcumin could be 
causing relaxation of the vascular smooth muscle cells, leading to vasodilation. Animal 
models have demonstrated vasoactive properties of curcumin that are time- and dose-
dependent (81). The ability of curcumin to affect vascular smooth muscle cells could be 
one possible mechanism by which curcumin affects brachial PP. 
Inflammation cannot be excluded as a possible mechanism. Although none of the 
pro-inflammatory markers changed, anti-inflammatory cytokine IL-10 increased (p = 
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0.071). IL-10 is a potent anti-inflammatory cytokine (107). Inflammation, when present, 
can affect the functional and structural arterial wall properties through increased reactive 
oxygen species, which lead to further inflammatory processes (231). These inflammatory 
processes can directly affect the arteries, produce changes through oxidative stress, or 
affect the smooth muscle cells mentioned above (276).  
Also, the role of endothelial function cannot be excluded as a possibility given the 
previously mentioned problems with measuring endothelial function using Endo-PAT 
2000. Notably, there is not sufficient evidence to support that the Endo-PAT 2000 is 
measuring NO-dependent vasodilation, and many studies have suggested that it measures 
more complex mechanisms (13, 85, 95). Endothelial function can affect vascular smooth 
muscle cell tone through NO bioavailability (315), and the previous study in PM women 
found that curcumin did affect endothelial function when measured by FMD; this change 
in FMD corresponded with reductions in SBP (8). Further studies should use FMD to 
determine if endothelial function could play a role in the reduction of brachial PP by 
curcumin.  
Lastly, any combination of vascular smooth muscle vasoactivity, inflammatory 
modulation via anti-inflammatory IL-10, and changes in endothelial function could have 
explained the significant changes in brachial PP by curcumin.  
Clinical Implications and Future Research 
The primary findings of this study demonstrated an effect of curcumin treatment 
on vascular stiffness. Future investigations with this curcumin compound will require a 
larger study population. Based on our calculations that incorporated the effect size found 
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in this study on the primary outcome (cfPWV), a post-hoc analysis to determine an 
appropriate sample size for a larger study with 80% power and significance of 0.05 
would include 176 obese men, matched and randomized by BMI. Therefore, from this 
study, we propose a future study with a larger sample of obese men that is sufficient to 
detect an overall treatment effect on arterial stiffness. 
 In the current study, obese men with stiffer arteries at baseline had reductions in 
arterial stiffness determined by cfPWV, which is the first time that this has been shown. 
This study has also shown that curcumin can beneficially affect brachial PP, which is a 
new finding that could be of great benefit in a clinical setting. It also confirms previous 
studies, that have shown that curcumin can reduce BP measures (8, 9). Therefore, this 
study shows promise for curcumin to improve vascular health, and it leaves some 
additional questions to be answered.   
The findings of this study may not be generalizable to every population, but these 
data seem to suggest that identifying populations with known elevated levels of cfPWV, 
such as an aging or diseased population, might allow the researchers to identify whether 
curcumin could be effective in ameliorating cfPWV. To further understand the impacts of 
curcumin on obesity, identifying and stratifying younger individuals with elevated 
cfPWV at baseline for inclusion in the study or identifying an older group of obese 
individuals should be considered. If individuals are stratified based on elevated cfPWV, 
smaller sample sizes may be sufficient to detect a treatment effect. Future studies should 
look at FMD to determine a potential role of endothelial function in the reduction of 
arterial stiffness, as measured by both cfPWV and brachial PP. Also, future studies 
looking at the modulation of arterial stiffness by curcumin should monitor anti-
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inflammatory blood markers IL-10 and IL-13 specifically. IL-10 may play a role in 
modulating the inflammatory processes that lead to reductions in brachial PP, while IL-
13 may play a role in modulating collagen structure that leads to reductions in cfPWV. 
Finally, this study showed a trending negative association with four-week 
consumption of whole grains, and a trending positive association with four-week 
consumption of refined grains. The roles of whole grains and refined grains as they relate 
to cfPWV have been relatively unexplored. A previous study found that whole grain 
consumption throughout the lifetime is associated with decreased stiffness of the carotid 
artery (348). The authors report that fiber content is responsible for the negative 
association between whole grains and carotid stiffness. However, other potential 
components of whole grains cannot be excluded, such as the vitamins, minerals, resistant 
starches, oligosaccharides, phenolic compounds, and phytoestrogens that are present in 
whole grains (308). Also, it is unknown whether the four-week dietary recall is reflective 
of regular lifetime patterns. Further work should look at these potentially novel predictors 
of cfPWV. 
Limitations  
There are several limitations of the current study. First, measurements of subjects 
were taken at different times of day due to limitations of lab space, which can potentially 
alter arterial stiffness, RHI, and inflammatory measures because of post-prandial status 
and diurnal variation (42, 98, 191, 346, 387). While it is preferable to take measurements 
at the same time of day due to these potential fluctuations, post-prandial status may be a 
more important consideration for cardiovascular measures when abdominal adiposity is 
present (46, 346). Specifically, IFN-γ, TNF-α, IL-1, and IL-12 exhibit diurnal variation, 
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characterized by a peak in the early morning (77, 260, 387). Since we were unable to 
control for each subject to come into the lab at the same time for each visit, restrictions 
were given for meal timing: an overnight fast including caffeinated beverages was 
required of morning subjects (preferred timing of testing), whereas a four hour fast 
including caffeinated beverages was required of individuals arriving in the afternoon or 
evening, thereby reducing the effects of post-prandial changes in arterial stiffness, RHI, 
and inflammation. These standards are in accordance with what is recommended by 
“Task Force III: Recommendations for user procedures” given for arterial stiffness 
measures (346). 
In addition, the 12 week duration of this study may not have been substantial 
enough time to see alterations in arterial stiffness. While curcumin has shown significant 
improvement in arterial compliance in humans after eight weeks of curcumin treatment 
(9), significant changes in arterial stiffness marked by cfPWV were not seen in humans 
after eight weeks in another study by the same group (322). After four weeks of curcumin 
treatment in mice, reductions were seen in cfPWV corresponding with amelioration of: 
structural changes in the arterial wall, endothelial dysfunction, AGEs, and oxidative 
stress (113). However, this study was conducted in mice, and the responsiveness in 
humans might require a longer time course. The current study did not find a significant 
change in overall cfPWV among the intervention group, though some individuals did see 
significant changes in arterial stiffness marked by cfPWV (responders). In this study, it is 
unknown whether the changes in cfPWV in the responders were due to structural changes 
in the arteries. 
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Also, the DHQ-II, a FFQ developed by the NIH, was used to account for dietary 
changes throughout the 12 week intervention, but FFQs are not always the most 
appropriate approach to detect subtle changes in dietary habits (115). In this study, 
dietary changes were considered for overall diet quality instead of subtle changes in 
dietary habits. Rather than the precise interaction of specific foods with arterial stiffness, 
this study was interested in an intervention that supposed a similar diet quality throughout 
the intervention period. Despite potential limitations, FFQs are commonly used in arterial 
stiffness studies (121, 157, 182, 193, 233, 270). Correlations for the DHQ, when 
compared to repeat 24-hour recalls collected over the course of a year, were r = 0.49 in 
men and r = 0.48 in women when assessing energy intake (319). Therefore, a moderate 
correlation exists between the DHQ and 24 hour recalls, which are frequently used in 
nutritional research.  
Finally, the role of physical activity was not assessed throughout the current 
study. Due to physical activity being a predictor of cfPWV (20, 245, 329), changes in 
activity patterns throughout this study could have affected arterial stiffness. Although the 
participants were instructed to maintain regular lifestyle habits throughout the duration of 
the study, including physical activity and exercise habits, we cannot ensure that all 
participants adhered to these guidelines.  
Final Conclusions 
 Curcumin ameliorates vascular function in obese men. This study provides the 
first evidence that curcumin ameliorates brachial PP, a clinically relevant marker of 
arterial stiffness. Moreover, the results of this study provide insight into a potential 
mechanism for the reduction in brachial PP through anti-inflammatory cytokine IL-10. 
 
 117 
 
Curcumin also decreases arterial stiffness via gold standard arterial stiffness marker, 
cfPWV, in obese men with elevated cfPWV measures. The prospective mechanism found 
in this study was increased anti-inflammatory cytokine IL-13, which corresponded with 
the reduction in cfPWV. This study gives support for curcumin in treating arterial 
dysfunction associated with obesity, which could lead to a reduction in future 
cardiovascular events. 
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APPENDIX 
Table A-1. Predicting inflammatory cytokines with waist circumference  
  β S.E. t statistic p-value R square Adjusted R square 
IFN-γ (pg/mL) 0.008 0.044 0.178 0.861 0.002 -0.057 
IL-2 (pg/mL) -0.002 0.007 -0.262 0.797 0.004 -0.055 
IL-4 (pg/mL) -0.001 0.002 -0.355 0.727 0.007 -0.051 
IL-6 (pg/mL) 0.008 0.006 1.261 0.224 0.086 0.032 
IL-8 (pg/mL) 0.031 0.013 2.355 0.031* 0.246 0.202 
IL-10 (pg/mL) -0.001 0.005 -0.240 0.813 0.003 -0.055 
IL-12 p70 (pg/mL) -0.001 0.007 -0.182 0.858 0.002 -0.057 
IL-13 (pg/mL) 0.156 0.124 1.262 0.224 0.086 0.032 
TNF-α (pg/mL) 0.021 0.008 2.580 0.019* 0.281 0.239 
*p < 0.05. IFN= Interferon; IL = Interleukin; TNF = Tumor Necrosis Factor 
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Table A-2. Univariate linear regression for correlations between baseline subject characteristics and cfPWV 
  β S.E. t statistic p-value R square Adjusted R square 
Age (years) 0.059 0.052 1.141 0.268 0.064 0.015 
Weight (kg) 0.008 0.015 0.514 0.612 0.014 -0.038 
BMI (kg/m2) 0.054 0.059 0.906 0.376 0.041 -0.009 
Hip circumference (cm) -0.021 0.030 -0.677 0.506 0.024 -0.028 
Waist circumference (cm) 0.012 0.020 0.625 0.540 0.020 -0.031 
Waist:hip ratio 7.480 3.703 2.020 0.058 0.177 0.133 
Waist:height ratio 2.523 3.434 0.735 0.472 0.028 -0.024 
Body fat % 0.024 0.040 0.609 0.550 0.019 -0.032 
Body fat (kg) 0.014 0.022 0.661 0.516 0.023 -0.029 
Lean mass (kg) 0.005 0.036 0.127 0.900 0.001 -0.052 
Brachial SBP (mmHg) 0.038 0.022 1.762 0.094 0.140 0.095 
Brachial DBP (mmHg) 0.041 0.025 1.672 0.111 0.128 0.082 
Brachial PP (mmHg)  0.006 0.024 0.256 0.801 0.003 -0.050 
Brachial MAP (mmHg)  0.053 0.026 2.006 0.059 0.175 0.131 
Central SBP (mmHg) 0.037 0.029 1.274 0.218 0.079 0.030 
Central DBP (mmHg)  0.044 0.024 1.817 0.085 0.148 0.103 
Central PP (mmHg) -0.038 0.039 -0.976 0.341 0.048 -0.002 
Central MAP (mmHg) 0.047 0.027 1.746 0.097 0.138 0.093 
IFN-γ (pg/mL) 0.023 0.108 0.213 0.834 0.003 -0.060 
IL-2 (pg/mL) 0.345 0.678 0.509 0.618 0.016 -0.046 
IL-4 (pg/mL) 3.146 2.771 1.135 0.273 0.075 0.017 
IL-6 (pg/mL) 0.517 0.774 0.669 0.513 0.027 -0.034 
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 Table A-2 (cont’d). Univariate linear regression for correlations between baseline subject characteristics and cfPWV 
  β S.E. t statistic p-value R square Adjusted R square 
IL-8 (pg/mL) 0.406 0.304 1.336 0.200 0.100 0.044 
IL-10 (pg/mL) 0.900 0.904 0.996 0.334 0.058 0.000 
IL-12 p70 (pg/mL) 1.479 0.626 2.362 0.031* 0.258 0.212 
IL-13 (pg/mL) 0.056 0.034 1.624 0.124 0.141 0.088 
TNF-α (pg/mL) 0.350 0.589 0.595 0.560 0.022 -0.040 
RHI 0.302 0.396 0.763 0.455 0.031 -0.022 
AIx (%) -0.005 0.018 -0.260 0.798 0.004 -0.052 
AIx75 (%) 0.008 0.017 0.480 0.637 0.013 -0.042 
Total HEI Score 0.016 0.015 1.111 0.281 0.061 0.012 
Total Vegetables (HEI Score) 0.139 0.177 0.784 0.443 0.031 -0.020 
Greens and Beans (HEI Score) -0.006 0.125 -0.044 0.965 0.000 -0.053 
Total Fruit (HEI Score) 0.168 0.114 1.473 0.157 0.103 0.055 
Whole Fruit (HEI Score) 0.151 0.105 1.434 0.168 0.098 0.050 
Refined Grains (HEI Score) 0.177 0.097 1.819 0.085 0.148 0.103 
Whole Grains (HEI Score) -0.359 0.175 -2.058 0.054 0.182 0.139 
Dairy (HEI Score) 0.039 0.083 0.465 0.647 0.011 -0.041 
Total Protein Foods (HEI Score) 0.422 0.411 1.026 0.318 0.052 0.003 
Seafood and Plant Proteins (HEI Score) 0.012 0.129 0.096 0.924 0.000 -0.052 
Fatty Acids  (HEI Score) 0.012 0.060 0.194 0.849 0.002 -0.051 
Sodium  (HEI Score) 0.063 0.085 0.744 0.466 0.028 -0.023 
Empty Calories  (HEI Score) 0.026 0.039 0.679 0.506 0.024 -0.028 
*p < 0.05. BMI = Body Mass Index; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; PP = Pulse Pressure; MAP = 
Mean Arterial Pressure; cfPWV = carotid-femoral Pulse Wave Velocity; RHI = Reactive Hyperemia Index; AIx = Augmentation 
Index; AIx75 = Augmentation Index Corrected for Heart Rate of 75; IFN = Interferon; IL = Interleukin; TNF = Tumor Necrosis Factor; 
HEI = Healthy Eating Index 
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Table A-3. Multiple linear regression for correlations between baseline subject characteristics and cfPWV 
  β S.E. F Value p-value R square Adjusted R square 
SBP 0.037 0.016 5.32 0.035* 0.249 0.202 
*p < 0.05. SBP = Systolic Blood Pressure  
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Table A-4. Univariate linear regression for correlations between baseline subject characteristics and RHI 
  β S.E. t statistic p-value R square Adjusted R square 
Age (years) 0.006 0.027 0.208 0.837 0.002 -0.05 
Weight (kg) -0.003 0.008 -0.334 0.742 0.006 -0.046 
BMI (kg/m2) -0.009 0.034 -0.260 0.797 0.004 -0.049 
Hip circumference (cm) -0.018 0.016 -1.114 0.279 0.061 0.012 
Waist circumference (cm) -0.013 0.010 -1.299 0.209 0.082 0.033 
Waist:Hip Ratio -2.432 2.147 -1.133 0.271 0.063 0.014 
Waist:height Ratio -2.190 1.783 -1.229 0.234 0.074 0.025 
Body fat % -0.030 0.022 -1.358 0.190 0.088 0.040 
Body fat (kg) -0.011 0.012 -0.904 0.377 0.041 -0.010 
Lean mass (kg) 0.011 0.019 0.604 0.553 0.019 -0.033 
Brachial SBP (mmHg) 0.009 0.013 0.684 0.502 0.024 -0.003 
Brachial DBP (mmHg) -0.024 0.014 -1.668 0.112 0.128 0.082 
Brachial PP (mmHg)  0.027 0.012 2.300 0.033* 0.218 0.177 
Brachial MAP (mmHg)  -0.021 0.016 -1.340 0.196 0.086 0.038 
Central SBP (mmHg) -0.007 0.017 -0.383 0.706 0.008 -0.045 
Central DBP (mmHg)  -2.000 0.014 -1.664 0.112 0.127 0.081 
Central PP (mmHg) 0.035 0.019 1.830 0.083 0.150 0.105 
Central MAP (mmHg) -0.021 0.016 -1.340 0.196 0.086 0.038 
IFN-γ (pg/mL) -0.014 0.015 -0.902 0.378 0.041 -0.009 
IL-2 (pg/mL) -0.035 0.062 -0.576 0.572 0.019 -0.039 
IL-4 (pg/mL) -0.103 0.390 -0.264 0.794 0.004 -0.054 
IL-6 (pg/mL) 0.740 1.640 0.451 0.658 0.012 -0.046 
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Table A-4 (cont’d). Univariate linear regression for correlations between baseline subject characteristics and RHI 
  β S.E. t statistic p-value R square Adjusted R square 
IL-8 (pg/mL) 0.030 0.181 0.167 0.869 0.002 -0.057 
IL-10 (pg/mL) 0.159 0.533 0.299 0.769 0.005 -0.053 
IL-12 p70 (pg/mL) -0.177 0.413 -0.282 0.781 0.005 -0.054 
IL-13 (pg/mL) 0.011 0.021 0.547 0.591 0.017 -0.041 
TNF-α (pg/mL) -0.175 0.277 -0.630 0.537 0.023 -0.035 
cfPWV (m/s) 0.104 0.136 0.763 0.455 31.000 -0.022 
AIx (%) -0.017 0.009 -1.851 0.080 0.153 0.108 
AIx75 (%) -0.019 0.008 -2.225 0.038* 0.207 0.165 
Total HEI Score 0.013 0.008 1.670 0.111 0.128 0.082 
Total Vegetables (HEI Score) 0.023 0.102 0.224 0.825 0.003 -0.050 
Greens and Beans (HEI Score) 0.038 0.071 0.538 0.597 0.015 -0.037 
Total Fruit (HEI Score) 0.077 0.069 1.109 0.281 0.011 0.502 
Whole Fruit (HEI Score) 0.084 0.060 1.397 0.179 0.045 0.493 
Refined Grains (HEI Score) 0.016 0.060 0.261 0.797 0.004 -0.049 
Whole Grains (HEI Score) 0.067 0.108 0.621 0.542 0.020 -0.032 
Dairy (HEI Score) -0.047 0.053 -0.895 0.382 0.040 -0.010 
Total Protein Foods (HEI Score) 0.089 0.183 0.483 0.634 0.012 -0.040 
Seafood and Plant Proteins (HEI Score) 0.066 0.073 0.905 0.377 0.041 -0.009 
Fatty Acids  (HEI Score) 0.047 0.031 1.524 0.144 0.109 0.062 
Sodium  (HEI Score) 0.053 0.043 1.239 0.230 0.075 0.026 
Empty Calories  (HEI Score) 0.022 0.018 1.218 0.238 0.072 0.024 
*p < 0.05. RHI = Reactive Hyperemia Index; BMI = Body Mass Index; SBP = Systolic Blood Pressure; DBP = Diastolic Blood 
Pressure; PP = Pulse Pressure; MAP = Mean Arterial Pressure; cfPWV = carotid-femoral Pulse Wave Velocity; AIx = Augmentation 
Index; AIx75 = Augmentation Index Corrected for Heart Rate of 75; IFN = Interferon; IL = Interleukin; TNF = Tumor Necrosis Factor; 
HEI = Healthy Eating Index 
 
  
 
124 
Table A-5. Univariate linear regression for correlations between baseline subject characteristics and Brachial SBP 
  β S.E. t statistic p-value R square Adjusted R square 
Age (years) 0.137 0.456 0.301 0.766 0.005 -0.045 
Weight (kg) 0.740 0.318 2.329 0.305 0.213 0.174 
BMI (kg/m2) 1.308 0.470 2.787 0.011* 0.280 0.244 
Hip circumference (cm) 0.386 0.253 1.523 0.143 0.104 0.059 
Waist circumference (cm) 0.411 0.146 2.804 0.011* 0.282 0.246 
Waist:Hip Ratio 101.733 29.758 3.419 0.003* 0.369 0.337 
Waist:height Ratio 70.625 26.505 2.665 0.015* 0.262 0.225 
Body fat % 0.670 0.346 1.937 0.067 0.158 0.116 
Body fat (kg) 0.424 0.182 2.334 0.030* 0.214 0.175 
Lean mass (kg) 0.480 0.304 1.578 0.130 0.111 0.066 
IFN-γ (pg/mL) 0.077 0.980 0.078 0.938 0.000 -0.058 
IL-2 (pg/mL) -4.490 6.065 -0.740 0.469 0.031 -0.026 
IL-4 (pg/mL) -7.656 25.918 -0.295 0.771 0.005 -0.053 
IL-6 (pg/mL) 6.320 6.482 0.975 0.343 0.053 -0.003 
IL-8 (pg/mL) 2.318 2.794 0.830 0.418 0.039 -0.018 
IL-10 (pg/mL) -5.702 8.303 -0.687 0.501 0.027 -0.030 
IL-12 p70 (pg/mL) 1.634 6.506 0.251 0.805 0.004 -0.055 
IL-13 (pg/mL) 0.457 0.313 1.461 0.162 0.112 0.059 
TNF-α (pg/mL) 3.460 4.337 0.798 0.436 0.036 -0.021 
*p < 0.05. SBP = Systolic Blood Pressure; BMI = Body Mass Index; IFN = Interferon; IL = Interleukin; TNF = Tumor Necrosis 
Factor 
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Table A-6. Univariate linear regression for correlations between baseline subject characteristics and Brachial DBP 
  β S.E. t statistic p-value R square Adjusted R square 
Age (years) 0.134 0.408 0.330 0.745 0.005 -0.044 
Weight (kg) 0.055 0.124 0.442 0.663 0.010 -0.040 
BMI (kg/m2) 0.530 0.481 1.103 0.283 0.057 0.010 
Hip circumference (cm) 0.067 0.239 0.281 0.782 0.004 -0.046 
Waist circumference (cm) 0.164 0.151 1.087 0.290 0.056 0.009 
Waist:Hip Ratio 53.713 31.293 1.716 0.102 -11.562 0.085 
Waist:height Ratio 36.543 26.372 1.386 0.181 0.088 0.042 
Body fat % 0.436 0.323 1.351 0.192 0.084 0.038 
Body fat (kg) 0.198 0.178 1.114 0.279 0.059 0.011 
Lean mass (kg) -0.204 0.285 -0.716 0.483 0.025 -0.024 
IFN-γ (pg/mL) 3.922 1.191 3.293 0.004* 0.389 0.354 
IL-2 (pg/mL) -1.308 5.770 -0.227 0.823 0.003 -0.056 
IL-4 (pg/mL) 0.910 24.367 0.037 0.971 0.000 -0.059 
IL-6 (pg/mL) -7.198 5.998 -1.200 0.247 0.078 0.024 
IL-8 (pg/mL) 2.582 2.598 0.994 0.334 0.055 -0.001 
IL-10 (pg/mL) -3.666 7.843 -0.467 0.646 0.013 -0.045 
IL-12 p70 (pg/mL) 4.530 6.013 0.753 0.462 0.032 -0.025 
IL-13 (pg/mL) 0.271 0.304 0.892 0.385 0.045 -0.011 
TNF-α (pg/mL) 0.497 4.141 0.120 0.906 -8.240 -0.058 
*p < 0.05. DBP = Diastolic Blood Pressure; BMI = Body Mass Index; IFN = Interferon; IL = Interleukin; TNF = Tumor Necrosis 
Factor 
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Table A-7. Univariate linear regression for correlations between baseline subject characteristics and Brachial PP 
  β S.E. t statistic p-value R square Adjusted R square 
Age (years) 0.003 0.455 0.007 0.995 0.000 -0.050 
Weight (kg) 0.233 0.129 1.812 0.085 0.141 0.098 
BMI (kg/m2) 0.778 0.523 1.489 0.152 0.100 0.055 
Hip circumference (cm) 0.319 0.257 1.241 0.229 0.072 0.025 
Waist circumference (cm) 0.248 0.163 1.517 0.145 0.103 0.058 
Waist:Hip Ratio 48.020 35.717 1.344 0.194 0.083 0.037 
Waist:height Ratio 34.082 29.761 1.145 0.266 0.062 0.015 
Body fat % 0.234 0.372 0.628 0.537 0.019 -0.030 
Body fat (kg) 0.226 0.198 1.142 0.267 0.061 0.014 
Lean mass (kg) 0.684 0.282 2.421 0.025* 0.227 0.188 
IFN-γ (pg/mL) 3.922 1.191 3.293 0.004* 0.389 0.354 
IL-2 (pg/mL) -3.182 6.452 -0.493 0.628 0.014 -0.044 
IL-4 (pg/mL) -8.567 27.323 -0.314 0.758 0.006 -0.053 
IL-6 (pg/mL) 13.519 6.212 2.176 0.044* 0.218 0.172 
IL-8 (pg/mL) -0.263 3.004 -0.088 0.931 0.001 -0.058 
IL-10 (pg/mL) -2.036 8.863 -0.230 0.821 0.003 -0.056 
IL-12 p70 (pg/mL) -2.896 6.838 -0.424 0.677 0.010 -0.048 
IL-13 (pg/mL) 0.186 0.347 0.535 0.600 0.017 -0.041 
TNF-α (pg/mL) 2.962 4.603 0.644 0.528 0.024 -0.034 
*p < 0.05. PP = Pulse Pressure; BMI = Body Mass Index; IFN = Interferon; IL = Interleukin; TNF = Tumor Necrosis Factor 
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Table A-8. Univariate linear regression for correlations between baseline subject characteristics and Brachial MAP 
  β S.E. t statistic p-value R square Adjusted R square 
Age (years) 0.135 0.366 0.370 0.715 0.007 -0.043 
Weight (kg) 0.133 0.108 1.226 0.234 0.070 0.023 
BMI (kg/m2) 0.790 0.408 1.934 0.067 0.158 0.115 
Hip circumference (cm) 0.173 0.212 0.819 0.422 0.032 -0.016 
Waist circumference (cm) 0.246 0.128 1.925 0.069 0.156 0.114 
Waist:Hip Ratio 69.720 25.778 2.705 0.014* 0.268 0.231 
Waist:height Ratio 47.904 22.383 2.140 0.045* 0.186 0.146 
Body fat % 0.514 0.280 1.833 0.082 0.144 0.101 
Body fat (kg) 0.274 0.153 1.787 0.089 0.138 0.095 
Lean mass (kg) 0.024 0.260 0.093 0.927 0.000 -0.050 
IFN-γ (pg/mL) 0.331 0.800 0.413 0.685 0.010 -0.048 
IL-2 (pg/mL) -2.369 5.020 -0.472 0.643 0.013 -0.045 
IL-4 (pg/mL) -1.945 21.303 -0.091 0.928 0.001 -0.058 
IL-6 (pg/mL) -2.692 5.423 -0.496 0.626 0.015 -0.044 
IL-8 (pg/mL) 2.494 2.257 1.105 0.285 0.067 0.012 
IL-10 (pg/mL) -4.345 6.822 -0.637 0.533 0.023 -0.034 
IL-12 p70 (pg/mL) 3.565 5.275 0.676 0.508 0.026 -0.031 
IL-13 (pg/mL) 0.333 0.260 1.283 0.217 0.088 0.035 
TNF-α (pg/mL) 1.484 3.60. 0.412 0.656 0.010 -0.048 
*p < 0.05. MAP = Mean Arterial Pressure; BMI = Body Mass Index; IFN = Interferon; IL = Interleukin; TNF = Tumor Necrosis 
Factor 
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Table A-9. Univariate linear regression for correlations between baseline subject characteristics and Central SBP 
  β S.E. t statistic p-value R square Adjusted R square 
Age (years) 0.370 0.350 1.059 0.302 0.053 0.006 
Weight (kg) 0.151 0.104 1.449 0.163 0.095 0.050 
BMI (kg/m2) 0.910 0.385 2.361 0.028* 0.218 0.179 
Hip circumference (cm) 0.274 0.201 1.364 0.188 0.085 0.040 
Waist circumference (cm) 0.319 0.116 2.757 0.012* 0.275 0.239 
Waist:Hip Ratio 82.204 23.000 3.575 0.002* 0.390 0.359 
Waist:height Ratio 61.665 19.947 3.091 0.006* 0.323 0.290 
Body fat % 0.542 0.270 2.003 0.059 0.167 0.125 
Body fat (kg) 0.291 0.148 1.975 0.062 0.163 0.121 
Lean mass (kg) 0.079 0.253 0.314 0.757 0.005 -0.045 
IFN-γ (pg/mL) 0.226 0.784 0.288 0.777 0.005 -0.054 
IL-2 (pg/mL) -3.497 4.865 -0.719 0.482 0.029 -0.028 
IL-4 (pg/mL) -8.368 20.724 -0.404 0.691 0.009 -0.049 
IL-6 (pg/mL) -0.710 5.335 -0.133 0.896 0.001 -0.058 
IL-8 (pg/mL) 2.135 2.224 0.960 0.351 0.051 -0.004 
IL-10 (pg/mL) -6.087 6.582 -0.925 0.368 0.048 -0.008 
IL-12 p70 (pg/mL) -0.118 6.863 -0.023 0.982 0.000 -0.059 
IL-13 (pg/mL) 0.274 0.257 1.063 0.303 0.062 0.007 
TNF-α (pg/mL) 3.331 3.447 0.966 0.347 0.052 -0.004 
*p < 0.05. SBP = Systolic Blood Pressure; BMI = Body Mass Index; IFN = Interferon; IL = Interleukin; TNF = Tumor Necrosis 
Factor 
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Table A-10. Univariate linear regression for correlations between baseline subject characteristics and Central DBP 
  β S.E. t statistic p-value R square Adjusted R square 
Age (years) 0.157 0.41 0.384 0.705 0.007 -0.042 
Weight (kg) 0.041 0.125 0.328 0.746 0.005 -0.044 
BMI (kg/m2) 0.492 0.485 1.015 0.322 0.049 0.001 
Hip circumference (cm) 0.046 0.241 0.193 0.849 0.002 -0.048 
Waist circumference (cm) 0.158 0.152 1.041 0.310 0.051 0.004 
Waist:Hip Ratio 54.832 31.377 1.748 0.096 0.132 0.090 
Waist:height Ratio 36.449 26.524 1.374 0.185 0.086 0.041 
Body fat % 0.409 0.326 1.254 0.224 0.073 0.027 
Body fat (kg) 0.181 0.180 1.006 0.326 0.048 0.001 
Lean mass (kg) -0.236 0.285 -0.826 0.418 0.033 -0.015 
IFN-γ (pg/mL) 0.437 0.918 0.476 0.640 0.013 -0.045 
IL-2 (pg/mL) -1.157 5.800 -0.200 0.844 0.002 -0.056 
IL-4 (pg/mL) 1.571 24.484 0.064 0.950 0.000 -0.059 
IL-6 (pg/mL) -6.816 6.056 -1.126 0.276 0.070 0.015 
IL-8 (pg/mL) 2.706 2.604 1.039 0.313 0.060 0.004 
IL-10 (pg/mL) -3.206 7.894 -0.406 0.690 0.010 -0.049 
IL-12 p70 (pg/mL) 4.814 6.030 0.798 0.436 0.036 -0.021 
IL-13 (pg/mL) 0.267 0.306 0.872 0.396 0.043 -0.014 
TNF-α (pg/mL) 0.890 4.158 0.214 0.833 0.003 -0.056 
*p < 0.05. DBP = Diastolic Blood Pressure; BMI = Body Mass Index; IFN = Interferon; IL = Interleukin; TNF = Tumor Necrosis 
Factor 
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Table A-11. Univariate linear regression for correlations between baseline subject characteristics and Central PP 
  β S.E. t statistic p-value R square Adjusted R square 
Age (years) 0.213 0.288 0.740 0.468 0.027 -0.022 
Weight (kg) 0.110 0.086 1.286 0.213 0.076 0.030 
BMI (kg/m2) 0.415 0.341 1.219 0.237 0.069 0.023 
Hip circumference (cm) 0.228 0.163 1.399 0.177 0.089 0.044 
Waist circumference (cm) 0.016 0.104 1.546 0.138 0.107 0.062 
Waist:Hip Ratio 27.372 23.112 1.184 0.250 0.066 0.019 
Waist:height Ratio 25.216 18.869 1.336 0.196 0.082 0.036 
Body fat % 0.132 0.239 0.554 0.586 0.015 -0.034 
Body fat (kg) 0.110 0.129 0.856 0.402 0.035 -0.013 
Lean mass (kg) 0.315 0.193 1.630 0.119 0.117 0.073 
IFN-γ (pg/mL) -0.211 0.673 -0.314 0.757 0.006 -0.053 
IL-2 (pg/mL) -2.340 4.205 -0.556 0.585 0.018 -0.040 
IL-4 (pg/mL) -9.939 17.730 -0.561 0.582 0.018 -0.040 
IL-6 (pg/mL) 6.107 4.341 1.407 0.178 0.104 0.052 
IL-8 (pg/mL) -0.571 1.957 -0.292 0.774 0.005 -0.054 
IL-10 (pg/mL) -2.881 5.754 -0.501 0.623 0.015 -0.043 
IL-12 p70 (pg/mL) -4.933 4.326 -1.140 0.270 0.071 0.016 
IL-13 (pg/mL) 0.007 0.228 0.031 0.976 0.000 -0.059 
TNF-α (pg/mL) 2.441 2.984 0.818 0.425 0.038 -0.019 
*p < 0.05. PP = Pulse Pressure; BMI = Body Mass Index; IFN = Interferon; IL = Interleukin; TNF = Tumor Necrosis Factor 
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Table A-12. Univariate linear regression for correlations between baseline subject characteristics and Central MAP 
  β S.E. t statistic p-value R square Adjusted R square 
Age (years) 0.228 0.367 0.623 0.541 0.019 -0.03 
Weight (kg) 0.078 0.112 0.697 0.494 0.024 -0.025 
BMI (kg/m2) 0.631 0.425 1.485 0.153 0.099 0.050 
Hip circumference (cm) 0.123 0.215 0.570 0.575 0.016 -0.033 
Waist circumference (cm) 0.212 0.132 1.606 0.124 0.114 0.070 
Waist:Hip Ratio 63.956 26.719 2.394 0.027* 0.223 0.184 
Waist:height Ratio 44.854 22.859 1.962 0.064 0.161 0.120 
Body fat % 0.453 0.288 1.577 0.131 0.111 0.066 
Body fat (kg) 0.218 0.159 1.373 0.185 0.086 0.040 
Lean mass (kg) -0.131 0.260 -0.504 0.620 0.013 -0.037 
IFN-γ (pg/mL) 0.367 0.816 0.449 0.659 0.012 -0.046 
IL-2 (pg/mL) -1.937 5.137 -0.377 0.711 0.008 -0.050 
IL-4 (pg/mL) -1.742 21.747 -0.080 0.937 0.000 -0.058 
IL-6 (pg/mL) -4.781 5.454 -0.877 0.393 0.043 -0.013 
IL-8 (pg/mL) 2.516 2.306 1.091 0.291 0.065 0.010 
IL-10 (pg/mL) -4.166 6.973 -0.597 0.558 0.021 -0.037 
IL-12 p70 (pg/mL) 3.170 5.402 0.587 0.565 0.020 -0.038 
IL-13 (pg/mL) 0.269 0.270 0.996 0.333 0.055 0.000 
TNF-α (pg/mL) 1.704 3.675 0.464 0.649 0.012 -0.046 
*p < 0.05. MAP = Mean Arterial Pressure; BMI = Body Mass Index; IFN = Interferon; IL = Interleukin; TNF = Tumor Necrosis 
Factor 
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